≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Collapsed vertebra, not elsewhere classified

DOID EFO Endpoint Browser PheWeb

M13_VERTEBCOLLAPSE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — M48.5
  • Cause of death: ICD-10 — M48.5

2 out of 7 registries used, show all original rules.

308

4. Check minimum number of events

None

308

5. Include endpoints

None

308

6. Filter based on genotype QC (FinnGen only)

301

Control definitions (FinnGen only)

Control exclude
M13_DORSOPATHY

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
M48
Name in latin
Vertebra collapsa non alibi classificata

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2977 1951 1011
Only index persons 2606 1732 874
Unadjusted period prevalence (%)
Whole population 0.05 0.06 0.03
Only index persons 0.05 0.06 0.03
Median age at first event (years)
Whole population 76.32 78.64 71.80
Only index persons 76.04 78.45 71.27

-FinnGen-

Key figures

All Female Male
Number of individuals 301 191 110
Unadjusted period prevalence (%) 0.06 0.07 0.05
Median age at first event (years) 73.41 74.46 71.58

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
308
Matched controls
3080
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M48.5
ICD-10 Finland
Collapsed vertebra, not elsewhere classified
+∞
307.7
308
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
22.3
122.9
102
67
M48.0
ICD-10 Finland
Spinal stenosis
44.5
99.8
61
17
S22.0
ICD-10 Finland
Fracture of thoracic vertebra
32.4
83.5
56
21
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
27.8
83.1
59
26
M54.5
ICD-10 Finland
Low back pain
8.7
82.1
170
383
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
8.5
75.2
136
262
S32.0
ICD-10 Finland
Fracture of lumbar vertebra
18.0
74.7
65
45
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
32.4
70.6
47
17
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
21.4
66.1
52
29
M54.9
ICD-10 Finland
Dorsalgia, unspecified
11.5
61.2
71
78
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
11.9
58.7
66
69
M80.9
ICD-10 Finland
Unspecified osteoporosis with pathological fracture
18.6
58.5
49
31
N03AX16
ATC
[U] pregabalin
7.1
58.5
119
252
N02AX02
ATC
tramadol; systemic, rectal
4.8
40.9
188
758
M80.0
ICD-10 Finland
Postmenopausal osteoporosis with pathological fracture
11.0
38.6
44
46
L03
ICPC
Low back symptom/complaint
4.8
37.9
124
382
N02AA05
ATC
oxycodone; systemic
4.7
37.7
130
417
M54.4
ICD-10 Finland
Lumbago with sciatica
6.5
35.1
65
121
N03AX12
ATC
[U] gabapentin; oral
5.7
33.3
73
159
M81.9
ICD-10 Finland
Osteoporosis, unspecified
6.9
33.1
57
98
M05BX04
ATC
denosumab; parenteral
6.2
32.5
63
122
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.1
31.4
200
964
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
177.9
31.3
32
*
M54.6
ICD-10 Finland
Pain in thoracic spine
9.6
31.2
39
46
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
3.6
27.4
178
845
M05BA04
ATC
alendronic acid; oral
4.4
27.2
84
241
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
153.4
27.1
28
*
L95
ICPC
Osteoporosis
6.9
26.3
44
73
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
55.2
25.7
30
6
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.9
25.2
50
98
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
58.9
23.5
27
5
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.4
22.8
123
508
N02BF02
ATC
pregabalin; oral
7.1
21.4
34
53
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
5.6
20.4
42
85
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
21.2
19.9
29
15
M54
ICD-10 Finland
Dorsalgia
5.0
19.7
47
108
N02BF01
ATC
gabapentin; oral
5.0
19.4
45
101
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.5
18.7
80
282
318
Kela drug reimbursment
Teriparatide
47.1
18.5
22
5
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.9
18.5
132
627
X59
ICD-10 Finland
Exposure to unspecified factor
3.4
18.3
82
297
L86
ICPC
Back syndrome with radiating pain
7.0
18.3
29
45
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
18.2
196
1153
L28
ICPC
Limited function/disability (L)
3.0
17.4
105
452
N06AX21
ATC
duloxetine; oral
4.7
17.3
43
102
C03CA01
ATC
furosemide; systemic
2.7
16.8
176
1006
M03BX02
ATC
tizanidine; oral
2.7
16.5
177
1021
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.7
16.1
137
703
M01AH02
ATC
rofecoxib; oral
3.5
16.0
65
220
N02AJ06
ATC
codeine and paracetamol; systemic
2.7
15.7
136
702
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
4.2
15.4
45
121
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.6
15.4
147
794
NE1AA
NOMESCO Finland
Pelvis X-ray examination
3.8
15.0
52
158
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
14.6
123
621
H05AA02
ATC
teriparatide; parenteral
38.1
14.6
18
5
JN3AD
NOMESCO Finland
Abdominal CT examination
3.4
14.6
61
210
A02BC01
ATC
omeprazole; systemic
2.6
13.6
114
571
Z01.8
ICD-10 Finland
Other specified special examinations
2.8
13.1
83
360
A06AD11
ATC
lactulose; oral
2.7
12.9
85
376
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.3
12.9
55
191
C07AB07
ATC
bisoprolol; oral
2.5
12.6
207
1392
L02
ICPC
Back symptom/complaint
3.8
12.6
42
124
AA1AD
NOMESCO Finland
CT of head and brain
2.4
12.6
129
705
ABC56
NOMESCO Finland
Decompression of lumbar spinal canal and nerve roots
135.3
12.5
13
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.0
12.5
65
253
R53
ICD-10 Finland
Malaise and fatigue
2.5
12.3
107
542
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.7
12.2
81
359
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.7
12.2
81
359
A02BC02
ATC
pantoprazole; systemic
2.6
12.1
234
1680
R52.9
ICD-10 Finland
Pain, unspecified
3.6
12.0
44
138
NA1AD
NOMESCO Finland
Cervical spine CT examination
5.1
11.9
26
55
NAG62
NOMESCO Finland
Posterior fusion of lumbar spine with fixation, 2-3 vertebraea
+∞
11.5
11
*
N06AX11
ATC
mirtazapine; oral
2.3
11.5
126
703
R4110
NOMESCO Finland
Physiotherapy
2.4
11.5
107
556
9732/3-C42.1
ICD-O-3
Plasma cell myeloma of bone marrow
13.4
11.3
19
15
C90.0
ICD-10 Finland
Multiple myeloma
11.8
11.2
20
18
N03AE01
ATC
clonazepam; systemic
5.0
11.2
25
54
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.9
11.1
58
226
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.1
10.9
50
181
S22.3
ICD-10 Finland
Fracture of rib
3.9
10.8
34
96
R07.4
ICD-10 Finland
Chest pain, unspecified
2.3
10.8
107
569
M43.1
ICD-10 Finland
Spondylolisthesis
22.4
10.8
15
7
N06AX16
ATC
venlafaxine; oral
3.2
10.8
46
159
NA3EA
NOMESCO Finland
Lumbar spine X-ray examination with flexion
62.2
10.7
12
*
N02BE01
ATC
paracetamol; systemic, rectal
4.1
10.7
286
2339
B01AB05
ATC
enoxaparin; parenteral
2.3
10.6
125
714
A02BC05
ATC
esomeprazole; systemic
2.2
10.6
135
796
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
12.7
10.5
18
15
I48
ICD-10 Finland
Atrial fibrillation and flutter
2.3
10.4
118
663
A07AA02
ATC
nystatin; oral
3.8
10.4
33
94
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.5
10.3
26
62
ZXD05
NOMESCO Finland
Urgent procedure
2.3
10.0
107
585
H02AB06
ATC
prednisolone; systemic
2.2
10.0
164
1063
Z3231
NOMESCO Finland
Registered nurse
2.3
9.9
102
548
A01
ICPC
Pain general/multiple sites
3.2
9.9
43
150
UJF32
NOMESCO Finland
Coloscopy
2.3
9.9
99
526
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
9.8
82
403
M03BC01
ATC
orphenadrine (citrate); systemic
2.7
9.7
57
235
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.5
9.7
71
327
K59.09
ICD-10 Finland
Constipation, unspecified
3.7
9.6
32
94
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
3.8
9.5
30
85
NA7EA
NOMESCO Finland
Scoliosis X-ray examination
31.1
9.5
12
*
M80.8
ICD-10 Finland
Other osteoporosis with pathological fracture
31.1
9.5
12
*
D07AC01
ATC
betamethasone; topical
2.2
9.4
125
741
X58
ICD-10 Finland
Exposure to other specified factors
2.8
9.4
51
202
R50.9
ICD-10 Finland
Fever, unspecified
2.6
9.3
60
260
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.6
9.3
63
280
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
4.3
9.2
24
59
F32.9
ICD-10 Finland
Depressive episode, unspecified
3.1
9.2
40
140
153
Kela drug reimbursment
Lenalidomid
16.2
9.1
14
9
A28
ICPC
Limited function/disability NOS
2.2
9.1
97
527
M01AH05
ATC
etoricoxib; oral
2.1
8.9
169
1139
M54.8
ICD-10 Finland
Other dorsalgia
8.0
8.8
19
25
Z3226
NOMESCO Finland
Physiotherapist
2.4
8.8
68
321
M51.8
ICD-10 Finland
Other specified intervertebral disc disorders
51.5
8.7
10
*
NA1AA
NOMESCO Finland
Cervical spine X-ray examination without contrast
8.6
8.7
18
22
R52.2
ICD-10 Finland
Other chronic pain
6.7
8.6
21
33
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
16.9
8.6
13
8
N04BC05
ATC
pramipexole; oral
3.2
8.6
36
123
M80.4
ICD-10 Finland
Drug-induced osteoporosis with pathological fracture
20.7
8.5
12
6
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.2
8.5
35
118
N05BA04
ATC
oxazepam; oral
2.2
8.5
97
539
SPAT1229
SPAT
Assessment of need for aid
3.1
8.5
38
135
B01AF02
ATC
apixaban; oral
2.4
8.5
68
326
A02BC03
ATC
lansoprazole; oral
2.1
8.3
103
590
L04AX04
ATC
lenalidomide; oral
15.0
8.3
13
9
329
Kela drug reimbursment
Lenalidomide
34.3
8.1
10
*
207
Kela drug reimbursment
Chronic arrhythmias
2.2
8.1
82
434
M05BA07
ATC
risedronic acid; oral
3.8
8.0
25
70
M79.6
ICD-10 Finland
Pain in limb
2.0
8.0
130
820
SPAT1255
SPAT
Intravenous administration of medicine
3.3
8.0
31
101
NF1AA
NOMESCO Finland
Hip X-ray examination
2.8
7.8
43
171
A02BA02
ATC
ranitidine; systemic
2.2
7.8
82
439
Z2446
NOMESCO Finland
Social worker
3.3
7.8
30
97
J01DB01
ATC
cefalexin; oral
2.3
7.8
248
1982
N30.0
ICD-10 Finland
Acute cystitis
2.3
7.7
68
338
A06AC01
ATC
ispaghula (psylla seeds); oral
2.1
7.7
98
565
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
2.2
7.7
80
427
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
18.9
7.7
11
6
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.9
7.7
38
143
M47.82
ICD-10 Finland
Other spondylosis, cervical region
12.3
7.6
13
11
NA2AD
NOMESCO Finland
Thoracic spine CT examination
25.7
7.6
10
*
ZXD10
NOMESCO Finland
Scheduled procedure
2.0
7.6
128
815
ZXA05
NOMESCO Finland
Left side
2.1
7.5
94
537
A97
ICPC
No disease
2.2
7.5
74
386
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
82.0
7.4
8
*
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
82.0
7.4
8
*
ZZH21
NOMESCO Finland
Graft of patients own bone, small pieces
13.8
7.4
12
9
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
2.5
7.4
50
220
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
3.7
7.4
24
69
ZXE20
NOMESCO Finland
More than three and less than five hours
2.5
7.4
53
240
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.2
7.4
78
417
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.0
7.4
35
128
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.9
7.4
36
134
WX892
NOMESCO Finland
Monitored bed care
3.0
7.4
33
117
WW402
NOMESCO Finland
Leucoferesis
+∞
7.3
7
*
ABC16
NOMESCO Finland
Microsurgical excision of lumbar intervertebral disc displacement
+∞
7.3
7
*
R5110, ,
SPAT
2.7
7.3
41
165
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.3
7.1
64
321
J01EA01
ATC
trimethoprim; systemic
2.0
7.1
108
662
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
2.5
7.0
46
200
W19
ICD-10 Finland
Unspecified fall
2.5
6.9
45
195
XF400
NOMESCO Finland
ECG with 12 standard connections
2.2
6.8
64
326
UKC02
NOMESCO Finland
Cystoscopy
2.3
6.8
57
277
M47.9
ICD-10 Finland
Spondylosis, unspecified
41.0
6.8
8
*
N02AC04
ATC
dextropropoxyphene; oral
3.9
6.8
20
54
L84
ICPC
Back syndrome without radiat pain
4.2
6.7
18
45
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
23.1
6.7
9
*
M01AC06
ATC
meloxicam; systemic, rectal
1.9
6.7
112
705
J05AB11
ATC
valaciclovir; oral
2.4
6.7
51
238
Z76.8
ICD-10 Finland
Persons encountering health services in other specified circumstances
4.0
6.6
19
50
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
4.0
6.6
19
50
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.0
6.6
30
107
D64.9
ICD-10 Finland
Anaemia, unspecified
2.3
6.6
56
273
J01FF01
ATC
clindamycin; systemic
2.0
6.6
87
504
NE1AD
NOMESCO Finland
Pelvis and hip bones CT examination
5.6
6.6
18
34
M81.0
ICD-10 Finland
Postmenopausal osteoporosis
3.7
6.6
21
60
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
5.9
6.6
17
30
A46
ICD-10 Finland
Erysipelas
2.2
6.5
61
311
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.3
6.4
51
242
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
2.6
6.4
38
157
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.1
6.4
69
371
N05BA12
ATC
alprazolam; oral
2.7
6.4
36
145
G04CA02
ATC
tamsulosin; oral
2.1
6.4
75
417
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.2
6.3
58
292
SPAT1260
SPAT
Consultation of another employee
2.2
6.3
63
328
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.2
6.3
62
321
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
1.9
6.3
106
666
NAG63
NOMESCO Finland
Posterior fusion of lumbar spine with fixation, more than 3 vertebraea
+∞
6.3
6
*
NAG66
NOMESCO Finland
Posterior interbody fusion of lumbar spine, 2 vertebrae
+∞
6.3
6
*
R56.8
ICD-10 Finland
Other and unspecified convulsions
3.5
6.3
22
67
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.9
6.3
95
577
N05AA02
ATC
levomepromazine; systemic
4.1
6.3
17
43
R30.0
ICD-10 Finland
Dysuria
4.1
6.3
17
43
Z02.7
ICD-10 Finland
Issue of medical certificate
2.9
6.2
29
105
B01AA03
ATC
warfarin; systemic
2.0
6.2
91
545
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
2.8
6.2
31
117
R06AE07
ATC
cetirizine; oral
1.9
6.2
121
797
N30.9
ICD-10 Finland
Cystitis, unspecified
2.7
6.2
33
129
N05BA01
ATC
diazepam; systemic, rectal
2.3
6.2
49
232
XF655
NOMESCO Finland
Measurement of heart muscle perfusion with exercise
4.3
6.2
16
39
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
4.3
6.2
16
39
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
4.3
6.2
16
39
A04AA01
ATC
ondansetron; systemic, rectal
2.7
6.1
35
142
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
3.5
6.1
21
63
M54.2
ICD-10 Finland
Cervicalgia
3.5
6.1
21
63
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
2.1
6.0
70
386
R35
ICD-10 Finland
Polyuria
3.3
6.0
23
74
SCA01
NOMESCO Finland
Preventive oral health care, short
2.0
6.0
75
425
M02AA07
ATC
piroxicam; topical
1.8
6.0
122
812

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
gabapentin; oral
N02BF01 [955005]
1.6e+00
2.4e+00
3.4e+00
—
3.2e+00
2.9e+00
2.2e+00
cases:6.19%
controls:1.37%
cases:6.84%
controls:0.65%
cases:4.56%
controls:0.16%
—
—
cases:3.97%
controls:0.16%
cases:10.64%
controls:0.68%
cases:15.35%
controls:1.91%
19
42
288
3024
21
20
286
3046
14
5
293
3061
—
12
5
290
3051
30
20
252
2917
33
44
182
2261
oxycodone; oral, parenteral
N02AA05 [21604260]
1.7e+00
2.4e+00
2.9e+00
1.0e+50
3.2e+00
2.5e+00
1.5e+00
cases:7.82%
controls:1.60%
cases:8.47%
controls:0.82%
cases:6.19%
controls:0.36%
cases:1.63%
controls:0.00%
cases:10.60%
controls:0.46%
cases:15.96%
controls:1.50%
cases:17.67%
controls:4.38%
24
49
283
3017
26
25
281
3041
19
11
288
3055
5
0
302
3066
32
14
270
3042
45
44
237
2893
38
101
177
2204
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
1.4e+00
2.4e+00
3.7e+00
—
2.9e+00
2.1e+00
1.5e+00
cases:19.22%
controls:5.38%
cases:17.26%
controls:1.92%
cases:11.07%
controls:0.29%
—
—
cases:8.61%
controls:0.49%
cases:12.77%
controls:1.80%
cases:16.28%
controls:4.16%
59
165
248
2901
53
59
254
3007
34
9
273
3057
—
26
15
276
3041
36
53
246
2884
35
96
180
2209
pregabalin; oral
N02BF02 [955152]
1.8e+00
2.0e+00
2.4e+00
—
2.3e+00
2.8e+00
2.5e+00
cases:13.03%
controls:2.45%
cases:8.79%
controls:1.24%
cases:4.89%
controls:0.46%
—
—
cases:4.97%
controls:0.52%
cases:16.31%
controls:1.23%
cases:20.00%
controls:2.08%
40
75
267
2991
27
38
280
3028
15
14
292
3052
—
15
16
287
3040
46
36
236
2901
43
48
172
2257
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
1.3e+00
2.2e+00
2.4e+00
—
3.1e+00
2.8e+00
1.8e+00
cases:6.84%
controls:1.89%
cases:11.40%
controls:1.37%
cases:6.84%
controls:0.65%
—
—
cases:10.93%
controls:0.56%
cases:20.21%
controls:1.50%
cases:20.47%
controls:3.95%
21
58
286
3008
35
42
272
3024
21
20
286
3046
—
33
17
269
3039
57
44
225
2893
44
91
171
2214
Hematology
82 [38004501]
1.6e+00
1.9e+00
2.4e+00
—
2.9e+00
2.8e+00
1.9e+00
cases:5.21%
controls:1.14%
cases:5.21%
controls:0.85%
cases:2.93%
controls:0.26%
—
—
cases:3.97%
controls:0.23%
cases:8.87%
controls:0.61%
cases:9.77%
controls:1.61%
16
35
291
3031
16
26
291
3040
9
8
298
3058
—
12
7
290
3049
25
18
257
2919
21
37
194
2268
Low back pain
M54.5 [45553207]
1.7e+00
2.8e+00
4.3e+00
—
—
2.5e+00
2.0e+00
cases:15.96%
controls:3.29%
cases:14.33%
controls:1.04%
cases:10.42%
controls:0.16%
—
—
—
—
cases:9.93%
controls:0.89%
cases:20.93%
controls:3.47%
49
101
258
2965
44
32
263
3034
32
5
275
3061
—
—
28
26
254
2911
45
80
170
2225
Physical Medicine And Rehabilitation
25 [38004468]
1.3e+00
2.7e+00
—
1.0e+50
3.9e+00
2.8e+00
1.6e+00
cases:11.73%
controls:3.49%
cases:12.70%
controls:0.98%
—
—
cases:18.24%
controls:0.00%
cases:7.28%
controls:0.16%
cases:16.31%
controls:1.23%
cases:18.60%
controls:4.30%
36
107
271
2959
39
30
268
3036
—
56
0
251
3066
22
5
280
3051
46
36
236
2901
40
99
175
2206
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
4.5e-01
9.2e-01
1.9e+00
4.1e+00
2.2e+00
1.0e+00
5.1e-01
cases:42.02%
controls:31.60%
cases:39.09%
controls:20.29%
cases:23.78%
controls:4.34%
cases:16.61%
controls:0.33%
cases:27.15%
controls:4.16%
cases:41.49%
controls:20.53%
cases:56.28%
controls:43.51%
129
969
178
2097
120
622
187
2444
73
133
234
2933
51
10
256
3056
82
127
220
2929
117
603
165
2334
121
1003
94
1302
Outpatient Visit
OP [9202]
6.6e-01
8.8e-01
1.0e+00
4.8e+00
1.3e+00
1.3e+00
9.8e-01
cases:86.97%
controls:77.46%
cases:75.57%
controls:56.10%
cases:26.06%
controls:11.51%
cases:30.29%
controls:0.36%
cases:32.45%
controls:11.19%
cases:81.56%
controls:55.70%
cases:92.56%
controls:82.34%
267
2375
40
691
232
1720
75
1346
80
353
227
2713
93
11
214
3055
98
342
204
2714
230
1636
52
1301
199
1898
16
407
Orthopedic Surgery
20 [38004465]
7.4e-01
1.8e+00
2.2e+00
1.0e+50
3.1e+00
2.0e+00
1.1e+00
cases:24.43%
controls:13.37%
cases:18.89%
controls:3.85%
cases:4.89%
controls:0.59%
cases:22.80%
controls:0.00%
cases:10.60%
controls:0.52%
cases:25.18%
controls:4.32%
cases:33.49%
controls:14.58%
75
410
232
2656
58
118
249
2948
15
18
292
3048
70
0
237
3066
32
16
270
3040
71
127
211
2810
72
336
143
1969
Low back symptom/complaint
L03 [2002000628]
1.2e+00
2.1e+00
3.6e+00
—
—
2.2e+00
1.7e+00
cases:8.47%
controls:2.84%
cases:8.79%
controls:1.17%
cases:5.86%
controls:0.16%
—
—
—
—
cases:9.22%
controls:1.16%
cases:16.28%
controls:3.56%
26
87
281
2979
27
36
280
3030
18
5
289
3061
—
—
26
34
256
2903
35
82
180
2223
Immunoglobulin light chains.free panel - Serum
57778-3 [40760888]
1.9e+00
2.7e+00
—
—
—
3.3e+00
2.5e+00
cases:2.28%
controls:0.36%
cases:2.28%
controls:0.16%
—
—
—
—
—
—
cases:4.61%
controls:0.17%
cases:5.12%
controls:0.43%
7
11
300
3055
7
5
300
3061
—
—
—
13
5
269
2932
11
10
204
2295
codeine and paracetamol
N02AJ06 [1123647]
1.1e+00
1.7e+00
2.6e+00
—
2.1e+00
1.6e+00
1.1e+00
cases:29.32%
controls:11.61%
cases:20.52%
controls:4.44%
cases:10.10%
controls:0.82%
—
—
cases:7.28%
controls:0.92%
cases:15.96%
controls:3.85%
cases:27.91%
controls:11.58%
90
356
217
2710
63
136
244
2930
31
25
276
3041
—
22
28
280
3028
45
113
237
2824
60
267
155
2038
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
1.1e+00
1.7e+00
2.3e+00
—
2.2e+00
1.3e+00
1.2e+00
cases:7.17%
controls:2.48%
cases:6.84%
controls:1.37%
cases:2.61%
controls:0.26%
—
—
cases:2.32%
controls:0.26%
cases:4.61%
controls:1.26%
cases:10.23%
controls:3.30%
22
76
285
2990
21
42
286
3024
8
8
299
3058
—
7
8
295
3048
13
37
269
2900
22
76
193
2229
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
1.2e+00
1.5e+00
2.2e+00
1.0e+50
2.4e+00
1.6e+00
7.8e-01
cases:9.45%
controls:3.00%
cases:8.14%
controls:1.86%
cases:3.26%
controls:0.36%
cases:1.95%
controls:0.00%
cases:3.31%
controls:0.29%
cases:9.22%
controls:2.01%
cases:12.56%
controls:6.16%
29
92
278
2974
25
57
282
3009
10
11
297
3055
6
0
301
3066
10
9
292
3047
26
59
256
2878
27
142
188
2163
pH of Serum or Plasma
2753-2 [3018418]
1.1e+00
1.5e+00
2.4e+00
—
2.4e+00
1.5e+00
8.4e-01
cases:18.89%
controls:7.18%
cases:14.98%
controls:3.65%
cases:5.21%
controls:0.49%
—
—
cases:6.29%
controls:0.62%
cases:15.96%
controls:3.98%
cases:21.86%
controls:10.80%
58
220
249
2846
46
112
261
2954
16
15
291
3051
—
19
19
283
3037
45
117
237
2820
47
249
168
2056
Thorax X-ray examination
GD1AA [2001303617]
1.2e+00
1.7e+00
2.3e+00
1.0e+50
2.1e+00
1.4e+00
1.1e+00
cases:26.06%
controls:9.92%
cases:15.96%
controls:3.49%
cases:4.89%
controls:0.52%
cases:3.58%
controls:0.00%
cases:2.65%
controls:0.33%
cases:13.83%
controls:3.95%
cases:28.37%
controls:11.67%
80
304
227
2762
49
107
258
2959
15
16
292
3050
11
0
296
3066
8
10
294
3046
39
116
243
2821
61
269
154
2036
calcitonin (salmon synthetic); nasal, parenteral
H05BA01 [21602787]
2.6e+00
3.2e+00
—
—
—
3.9e+00
—
cases:4.23%
controls:0.33%
cases:4.56%
controls:0.20%
—
—
—
—
—
—
cases:7.45%
controls:0.17%
—
—
13
10
294
3056
14
6
293
3060
—
—
—
21
5
261
2932
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
9.2e-01
1.4e+00
2.4e+00
1.0e+50
2.7e+00
1.5e+00
7.5e-01
cases:26.06%
controls:12.30%
cases:23.45%
controls:6.98%
cases:9.12%
controls:0.91%
cases:1.63%
controls:0.00%
cases:14.57%
controls:1.18%
cases:26.60%
controls:7.63%
cases:33.49%
controls:19.26%
80
377
227
2689
72
214
235
2852
28
28
279
3038
5
0
302
3066
44
36
258
3020
75
224
207
2713
72
444
143
1861
Kappa light chains.free [Mass/volume] in Serum
36916-5 [3034860]
2.2e+00
2.6e+00
—
—
—
3.0e+00
1.8e+00
cases:3.58%
controls:0.42%
cases:3.91%
controls:0.29%
—
—
—
—
—
—
cases:6.74%
controls:0.37%
cases:6.05%
controls:1.04%
11
13
296
3053
12
9
295
3057
—
—
—
19
11
263
2926
13
24
202
2281
Lambda light chains.free [Mass/volume] in Serum or Plasma
33944-0 [3047169]
2.2e+00
2.6e+00
—
—
—
3.0e+00
1.8e+00
cases:3.58%
controls:0.42%
cases:3.91%
controls:0.29%
—
—
—
—
—
—
cases:6.74%
controls:0.37%
cases:6.05%
controls:1.04%
11
13
296
3053
12
9
295
3057
—
—
—
19
11
263
2926
13
24
202
2281
Osteoporosis, unspecified
M81.9 [45591963]
1.9e+00
2.3e+00
—
—
—
3.2e+00
2.2e+00
cases:4.23%
controls:0.68%
cases:1.95%
controls:0.20%
—
—
—
—
—
—
cases:5.32%
controls:0.24%
cases:8.84%
controls:1.04%
13
21
294
3045
6
6
301
3060
—
—
—
15
7
267
2930
19
24
196
2281
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
1.1e+00
1.5e+00
2.3e+00
—
2.2e+00
1.2e+00
1.2e+00
cases:5.54%
controls:1.99%
cases:4.89%
controls:1.11%
cases:2.28%
controls:0.23%
—
—
cases:1.99%
controls:0.23%
cases:4.61%
controls:1.40%
cases:8.84%
controls:2.73%
17
61
290
3005
15
34
292
3032
7
7
300
3059
—
6
7
296
3049
13
41
269
2896
19
63
196
2242
Kappa light chains/Lambda light chains [Mass Ratio] in Serum
15189-4 [3007778]
2.1e+00
2.5e+00
—
—
—
3.0e+00
1.7e+00
cases:3.26%
controls:0.42%
cases:3.58%
controls:0.29%
—
—
—
—
—
—
cases:6.38%
controls:0.34%
cases:5.12%
controls:0.95%
10
13
297
3053
11
9
296
3057
—
—
—
18
10
264
2927
11
22
204
2283
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
8.9e-01
1.3e+00
2.2e+00
—
2.5e+00
1.5e+00
7.1e-01
cases:23.13%
controls:11.02%
cases:19.54%
controls:5.97%
cases:7.49%
controls:0.88%
—
—
cases:11.26%
controls:0.98%
cases:23.40%
controls:6.26%
cases:27.44%
controls:15.70%
71
338
236
2728
60
183
247
2883
23
27
284
3039
—
34
30
268
3026
66
184
216
2753
59
362
156
1943
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
6.6e-01
1.7e+00
2.6e+00
—
2.4e+00
1.7e+00
8.2e-01
cases:9.77%
controls:5.28%
cases:11.07%
controls:2.28%
cases:3.26%
controls:0.26%
—
—
cases:4.97%
controls:0.46%
cases:11.35%
controls:2.21%
cases:21.40%
controls:10.67%
30
162
277
2904
34
70
273
2996
10
8
297
3058
—
15
14
287
3042
32
65
250
2872
46
246
169
2059
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]
2.1e+00
2.4e+00
—
—
—
3.1e+00
1.6e+00
cases:4.89%
controls:0.65%
cases:3.91%
controls:0.36%
—
—
—
—
—
—
cases:5.67%
controls:0.27%
cases:5.12%
controls:1.13%
15
20
292
3046
12
11
295
3055
—
—
—
16
8
266
2929
11
26
204
2279
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]
2.0e+00
2.4e+00
—
—
—
3.1e+00
1.6e+00
cases:4.89%
controls:0.68%
cases:3.91%
controls:0.36%
—
—
—
—
—
—
cases:5.67%
controls:0.27%
cases:5.12%
controls:1.13%
15
21
292
3045
12
11
295
3055
—
—
—
16
8
266
2929
11
26
204
2279
Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2868-8 [3005229]
2.0e+00
2.4e+00
—
—
—
3.1e+00
1.6e+00
cases:4.89%
controls:0.68%
cases:3.91%
controls:0.36%
—
—
—
—
—
—
cases:5.67%
controls:0.27%
cases:5.12%
controls:1.13%
15
21
292
3045
12
11
295
3055
—
—
—
16
8
266
2929
11
26
204
2279
INR in Blood by Coagulation assay
34714-6 [3032080]
7.2e-01
8.7e-01
8.9e-01
3.4e+00
1.3e+00
1.0e+00
8.9e-01
cases:23.78%
controls:13.14%
cases:16.94%
controls:7.86%
cases:7.82%
controls:3.36%
cases:4.56%
controls:0.16%
cases:9.60%
controls:2.91%
cases:19.15%
controls:7.69%
cases:32.56%
controls:16.53%
73
403
234
2663
52
241
255
2825
24
103
283
2963
14
5
293
3061
29
89
273
2967
54
226
228
2711
70
381
145
1924
Differential panel, method unspecified - Blood
69738-3 [42870588]
1.2e+00
1.5e+00
2.2e+00
—
1.5e+00
1.6e+00
1.0e+00
cases:19.87%
controls:7.05%
cases:14.66%
controls:3.82%
cases:6.19%
controls:0.75%
—
—
cases:4.30%
controls:0.98%
cases:16.31%
controls:3.68%
cases:21.86%
controls:9.24%
61
216
246
2850
45
117
262
2949
19
23
288
3043
—
13
30
289
3026
46
108
236
2829
47
213
168
2092
Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis
51435-6 [3029713]
1.8e+00
2.4e+00
—
—
—
3.1e+00
1.6e+00
cases:4.56%
controls:0.75%
cases:3.91%
controls:0.36%
—
—
—
—
—
—
cases:5.67%
controls:0.27%
cases:5.12%
controls:1.13%
14
23
293
3043
12
11
295
3055
—
—
—
16
8
266
2929
11
26
204
2279
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
1.1e+00
1.4e+00
2.4e+00
1.0e+50
2.5e+00
1.5e+00
7.2e-01
cases:8.79%
controls:3.00%
cases:7.49%
controls:1.92%
cases:3.91%
controls:0.36%
cases:1.95%
controls:0.00%
cases:2.98%
controls:0.26%
cases:8.16%
controls:2.01%
cases:12.56%
controls:6.55%
27
92
280
2974
23
59
284
3007
12
11
295
3055
6
0
301
3066
9
8
293
3048
23
59
259
2878
27
151
188
2154
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
9.8e-01
1.5e+00
2.3e+00
—
2.3e+00
1.2e+00
6.5e-01
cases:11.07%
controls:4.47%
cases:11.07%
controls:2.84%
cases:2.28%
controls:0.23%
—
—
cases:3.64%
controls:0.39%
cases:10.99%
controls:3.47%
cases:18.60%
controls:10.63%
34
137
273
2929
34
87
273
2979
7
7
300
3059
—
11
12
291
3044
31
102
251
2835
40
245
175
2060
enoxaparin; parenteral
B01AB05 [21600976]
8.7e-01
1.6e+00
2.4e+00
—
2.7e+00
1.2e+00
5.7e-01
cases:11.40%
controls:5.12%
cases:7.82%
controls:1.63%
cases:2.93%
controls:0.26%
—
—
cases:3.31%
controls:0.23%
cases:5.32%
controls:1.67%
cases:9.30%
controls:5.47%
35
157
272
2909
24
50
283
3016
9
8
298
3058
—
10
7
292
3049
15
49
267
2888
20
126
195
2179
Bacteria [Presence] in Urine
87829-8 [36304419]
8.1e-01
1.4e+00
2.2e+00
1.0e+50
2.1e+00
1.4e+00
9.8e-01
cases:13.36%
controls:6.39%
cases:11.73%
controls:3.33%
cases:5.21%
controls:0.59%
cases:2.61%
controls:0.00%
cases:4.64%
controls:0.59%
cases:11.70%
controls:3.30%
cases:22.33%
controls:9.72%
41
196
266
2870
36
102
271
2964
16
18
291
3048
8
0
299
3066
14
18
288
3038
33
97
249
2840
48
224
167
2081
General Practice
1 [38004446]
8.1e-01
1.4e+00
2.3e+00
—
2.5e+00
1.2e+00
6.7e-01
cases:33.88%
controls:18.49%
cases:25.41%
controls:8.09%
cases:8.47%
controls:0.95%
—
—
cases:14.57%
controls:1.44%
cases:24.82%
controls:8.65%
cases:39.53%
controls:25.08%
104
567
203
2499
78
248
229
2818
26
29
281
3037
—
44
44
258
3012
70
254
212
2683
85
578
130
1727
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
3.9e-01
6.8e-01
1.8e+00
3.8e+00
1.8e+00
6.1e-01
3.8e-01
cases:34.85%
controls:26.52%
cases:35.50%
controls:21.89%
cases:22.80%
controls:4.53%
cases:13.03%
controls:0.33%
cases:25.50%
controls:5.17%
cases:34.75%
controls:22.37%
cases:46.98%
controls:37.74%
107
813
200
2253
109
671
198
2395
70
139
237
2927
40
10
267
3056
77
158
225
2898
98
657
184
2280
101
870
114
1435
Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2865-4 [3015322]
1.9e+00
2.3e+00
—
—
—
2.9e+00
1.6e+00
cases:4.56%
controls:0.68%
cases:3.58%
controls:0.36%
—
—
—
—
—
—
cases:4.96%
controls:0.27%
cases:5.12%
controls:1.13%
14
21
293
3045
11
11
296
3055
—
—
—
14
8
268
2929
11
26
204
2279
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
3.4e-01
5.2e-01
1.8e+00
4.1e+00
1.9e+00
5.2e-01
2.9e-01
cases:47.56%
controls:39.20%
cases:43.65%
controls:31.60%
cases:25.08%
controls:5.38%
cases:15.96%
controls:0.33%
cases:30.46%
controls:6.28%
cases:44.68%
controls:32.48%
cases:61.40%
controls:54.45%
146
1202
161
1864
134
969
173
2097
77
165
230
2901
49
10
258
3056
92
192
210
2864
126
954
156
1983
132
1255
83
1050
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
9.7e-01
1.3e+00
1.6e+00
1.0e+50
2.2e+00
1.7e+00
8.0e-01
cases:14.01%
controls:5.81%
cases:10.10%
controls:2.84%
cases:2.61%
controls:0.52%
cases:1.63%
controls:0.00%
cases:2.65%
controls:0.29%
cases:11.35%
controls:2.28%
cases:15.35%
controls:7.51%
43
178
264
2888
31
87
276
2979
8
16
299
3050
5
0
302
3066
8
9
294
3047
32
67
250
2870
33
173
182
2132
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
3.4e-01
5.3e-01
1.7e+00
4.1e+00
1.9e+00
4.6e-01
2.9e-01
cases:47.56%
controls:39.33%
cases:44.30%
controls:31.83%
cases:25.41%
controls:5.61%
cases:15.96%
controls:0.33%
cases:30.79%
controls:6.45%
cases:44.33%
controls:33.37%
cases:61.86%
controls:54.71%
146
1206
161
1860
136
976
171
2090
78
172
229
2894
49
10
258
3056
93
197
209
2859
125
980
157
1957
133
1261
82
1044
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
9.1e-01
1.4e+00
1.6e+00
—
1.9e+00
1.7e+00
1.1e+00
cases:12.38%
controls:5.38%
cases:8.79%
controls:2.22%
cases:3.26%
controls:0.68%
—
—
cases:3.31%
controls:0.49%
cases:9.57%
controls:1.94%
cases:15.81%
controls:5.99%
38
165
269
2901
27
68
280
2998
10
21
297
3045
—
10
15
292
3041
27
57
255
2880
34
138
181
2167
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
7.8e-01
1.4e+00
1.9e+00
1.0e+50
2.1e+00
1.4e+00
1.0e+00
cases:17.59%
controls:8.90%
cases:14.33%
controls:3.85%
cases:5.21%
controls:0.78%
cases:2.93%
controls:0.00%
cases:6.29%
controls:0.82%
cases:15.96%
controls:4.53%
cases:28.37%
controls:12.75%
54
273
253
2793
44
118
263
2948
16
24
291
3042
9
0
298
3066
19
25
283
3031
45
133
237
2804
61
294
154
2011
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
7.1e-01
1.0e+00
2.1e+00
—
2.5e+00
1.6e+00
6.5e-01
cases:17.26%
controls:9.33%
cases:13.36%
controls:5.15%
cases:3.91%
controls:0.49%
—
—
cases:6.95%
controls:0.62%
cases:22.34%
controls:5.41%
cases:27.44%
controls:16.44%
53
286
254
2780
41
158
266
2908
12
15
295
3051
—
21
19
281
3037
63
159
219
2778
59
379
156
1926
Leukocytes [#/volume] in Urine
30405-5 [3018095]
7.8e-01
1.4e+00
2.1e+00
1.0e+50
2.0e+00
1.4e+00
9.0e-01
cases:16.29%
controls:8.19%
cases:15.31%
controls:4.17%
cases:5.86%
controls:0.78%
cases:3.26%
controls:0.00%
cases:5.96%
controls:0.82%
cases:17.38%
controls:5.04%
cases:29.30%
controls:14.45%
50
251
257
2815
47
128
260
2938
18
24
289
3042
10
0
297
3066
18
25
284
3031
49
148
233
2789
63
333
152
1972
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
8.0e-01
1.3e+00
2.1e+00
1.0e+50
2.1e+00
1.3e+00
9.2e-01
cases:14.01%
controls:6.82%
cases:12.05%
controls:3.46%
cases:5.21%
controls:0.65%
cases:2.61%
controls:0.00%
cases:4.97%
controls:0.65%
cases:12.06%
controls:3.61%
cases:22.79%
controls:10.54%
43
209
264
2857
37
106
270
2960
16
20
291
3046
8
0
299
3066
15
20
287
3036
34
106
248
2831
49
243
166
2062
Osteoporosis
L95 [2002000714]
1.7e+00
2.5e+00
—
—
—
2.4e+00
2.0e+00
cases:2.61%
controls:0.49%
cases:2.61%
controls:0.23%
—
—
—
—
—
—
cases:3.55%
controls:0.34%
cases:7.91%
controls:1.13%
8
15
299
3051
8
7
299
3059
—
—
—
10
10
272
2927
17
26
198
2279
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
1.6e+00
2.3e+00
—
—
—
3.1e+00
1.5e+00
cases:5.86%
controls:1.27%
cases:5.21%
controls:0.52%
—
—
—
—
—
—
cases:9.57%
controls:0.48%
cases:7.91%
controls:1.87%
18
39
289
3027
16
16
291
3050
—
—
—
27
14
255
2923
17
43
198
2262
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
8.9e-01
1.3e+00
2.3e+00
—
2.3e+00
1.1e+00
6.6e-01
cases:10.75%
controls:4.73%
cases:9.77%
controls:2.94%
cases:2.61%
controls:0.26%
—
—
cases:3.64%
controls:0.39%
cases:9.93%
controls:3.47%
cases:16.74%
controls:9.41%
33
145
274
2921
30
90
277
2976
8
8
299
3058
—
11
12
291
3044
28
102
254
2835
36
217
179
2088
Emergency Medicine
93 [38004510]
5.7e-01
1.2e+00
2.7e+00
—
2.3e+00
1.1e+00
6.1e-01
cases:24.10%
controls:15.20%
cases:22.48%
controls:7.83%
cases:13.36%
controls:1.08%
—
—
cases:7.28%
controls:0.79%
cases:22.70%
controls:9.30%
cases:37.21%
controls:24.34%
74
466
233
2600
69
240
238
2826
41
33
266
3033
—
22
24
280
3032
64
273
218
2664
80
561
135
1744
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
6.8e-01
1.4e+00
2.1e+00
1.0e+50
1.9e+00
1.3e+00
9.1e-01
cases:14.33%
controls:7.80%
cases:13.36%
controls:3.82%
cases:5.54%
controls:0.72%
cases:2.61%
controls:0.00%
cases:5.63%
controls:0.85%
cases:14.18%
controls:4.19%
cases:26.05%
controls:12.45%
44
239
263
2827
41
117
266
2949
17
22
290
3044
8
0
299
3066
17
26
285
3030
40
123
242
2814
56
287
159
2018
Inpatient Hospital
21 [8717]
9.2e-01
1.1e+00
2.0e+00
—
2.1e+00
1.3e+00
8.4e-01
cases:57.00%
controls:34.54%
cases:28.99%
controls:11.84%
cases:10.42%
controls:1.60%
—
—
cases:15.56%
controls:2.16%
cases:30.14%
controls:10.28%
cases:46.51%
controls:27.20%
175
1059
132
2007
89
363
218
2703
32
49
275
3017
—
47
66
255
2990
85
302
197
2635
100
627
115
1678
duloxetine; oral
N06AX21 [21604749]
1.6e+00
2.0e+00
—
—
2.1e+00
2.8e+00
1.9e+00
cases:3.58%
controls:0.75%
cases:3.58%
controls:0.52%
—
—
—
—
cases:1.66%
controls:0.20%
cases:5.67%
controls:0.37%
cases:7.44%
controls:1.17%
11
23
296
3043
11
16
296
3050
—
—
5
6
297
3050
16
11
266
2926
16
27
199
2278
fentanyl; nasal, sublingual, transdermal
N02AB03 [21604272]
1.5e+00
2.7e+00
—
—
—
2.9e+00
2.6e+00
cases:1.63%
controls:0.36%
cases:2.93%
controls:0.20%
—
—
—
—
—
—
cases:5.32%
controls:0.31%
cases:6.51%
controls:0.52%
5
11
302
3055
9
6
298
3060
—
—
—
15
9
267
2928
14
12
201
2293
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
1.2e+00
1.7e+00
2.2e+00
—
—
1.5e+00
1.5e+00
cases:7.49%
controls:2.28%
cases:4.56%
controls:0.88%
cases:1.95%
controls:0.23%
—
—
—
—
cases:4.61%
controls:1.06%
cases:7.91%
controls:1.87%
23
70
284
2996
14
27
293
3039
6
7
301
3059
—
—
13
31
269
2906
17
43
198
2262
Internal Medicine
11 [38004456]
1.0e+00
1.2e+00
1.5e+00
—
1.8e+00
1.4e+00
1.2e+00
cases:49.84%
controls:26.32%
cases:27.36%
controls:10.47%
cases:7.49%
controls:1.70%
—
—
cases:9.60%
controls:1.73%
cases:30.14%
controls:9.77%
cases:50.23%
controls:23.82%
153
807
154
2259
84
321
223
2745
23
52
284
3014
—
29
53
273
3003
85
287
197
2650
108
549
107
1756
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
1.6e+00
2.2e+00
—
—
—
2.9e+00
1.3e+00
cases:6.84%
controls:1.44%
cases:5.86%
controls:0.65%
—
—
—
—
—
—
cases:9.22%
controls:0.58%
cases:8.37%
controls:2.39%
21
44
286
3022
18
20
289
3046
—
—
—
26
17
256
2920
18
55
197
2250
Monocytes/Leukocytes in Blood
26485-3 [3019069]
1.0e+00
1.3e+00
2.0e+00
—
1.5e+00
1.3e+00
8.5e-01
cases:23.78%
controls:10.14%
cases:17.59%
controls:5.64%
cases:7.49%
controls:1.04%
—
—
cases:5.30%
controls:1.24%
cases:19.50%
controls:5.99%
cases:26.98%
controls:13.58%
73
311
234
2755
54
173
253
2893
23
32
284
3034
—
16
38
286
3018
55
176
227
2761
58
313
157
1992
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
1.0e+00
1.3e+00
2.0e+00
—
1.5e+00
1.3e+00
8.5e-01
cases:23.45%
controls:10.11%
cases:17.59%
controls:5.74%
cases:7.49%
controls:1.04%
—
—
cases:5.30%
controls:1.24%
cases:19.50%
controls:5.92%
cases:26.98%
controls:13.62%
72
310
235
2756
54
176
253
2890
23
32
284
3034
—
16
38
286
3018
55
174
227
2763
58
314
157
1991
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.0e+00
1.3e+00
2.0e+00
—
1.5e+00
1.3e+00
8.5e-01
cases:23.45%
controls:10.11%
cases:17.59%
controls:5.71%
cases:7.49%
controls:1.08%
—
—
cases:5.30%
controls:1.24%
cases:19.50%
controls:5.92%
cases:26.98%
controls:13.67%
72
310
235
2756
54
175
253
2891
23
33
284
3033
—
16
38
286
3018
55
174
227
2763
58
315
157
1990
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
1.0e+00
1.2e+00
2.0e+00
—
1.5e+00
1.3e+00
8.3e-01
cases:23.78%
controls:10.21%
cases:17.26%
controls:5.77%
cases:7.49%
controls:1.04%
—
—
cases:5.30%
controls:1.18%
cases:18.44%
controls:5.89%
cases:26.51%
controls:13.58%
73
313
234
2753
53
177
254
2889
23
32
284
3034
—
16
36
286
3020
52
173
230
2764
57
313
158
1992
Emergency Room Visit
ER [9203]
8.7e-01
1.3e+00
1.6e+00
1.0e+50
1.7e+00
1.4e+00
1.1e+00
cases:55.70%
controls:34.57%
cases:32.90%
controls:12.17%
cases:9.12%
controls:1.89%
cases:24.43%
controls:0.00%
cases:8.61%
controls:1.64%
cases:34.04%
controls:11.71%
cases:59.07%
controls:33.41%
171
1060
136
2006
101
373
206
2693
28
58
279
3008
75
0
232
3066
26
50
276
3006
96
344
186
2593
127
770
88
1535
General Surgery
2 [38004447]
4.5e-01
1.3e+00
2.2e+00
—
2.2e+00
1.4e+00
7.5e-01
cases:25.73%
controls:18.04%
cases:15.64%
controls:4.96%
cases:6.19%
controls:0.72%
—
—
cases:6.29%
controls:0.72%
cases:15.60%
controls:4.46%
cases:23.72%
controls:12.75%
79
553
228
2513
48
152
259
2914
19
22
288
3044
—
19
22
283
3034
44
131
238
2806
51
294
164
2011
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.4e-01
4.5e-01
1.5e+00
3.6e+00
1.7e+00
5.1e-01
1.3e-01
cases:34.20%
controls:28.93%
cases:34.53%
controls:25.18%
cases:19.54%
controls:5.02%
cases:11.73%
controls:0.36%
cases:25.17%
controls:5.56%
cases:37.59%
controls:26.56%
cases:44.65%
controls:41.34%
105
887
202
2179
106
772
201
2294
60
154
247
2912
36
11
271
3055
76
170
226
2886
106
780
176
2157
96
953
119
1352
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
1.0e+00
1.2e+00
1.8e+00
—
1.5e+00
1.3e+00
8.7e-01
cases:25.08%
controls:10.63%
cases:18.89%
controls:6.33%
cases:7.17%
controls:1.21%
—
—
cases:5.96%
controls:1.34%
cases:20.21%
controls:6.44%
cases:29.77%
controls:15.10%
77
326
230
2740
58
194
249
2872
22
37
285
3029
—
18
41
284
3015
57
189
225
2748
64
348
151
1957
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
1.0e+00
1.2e+00
1.9e+00
—
1.5e+00
1.2e+00
8.6e-01
cases:24.43%
controls:10.31%
cases:17.59%
controls:5.81%
cases:7.17%
controls:1.11%
—
—
cases:5.30%
controls:1.21%
cases:18.44%
controls:6.20%
cases:27.44%
controls:13.84%
75
316
232
2750
54
178
253
2888
22
34
285
3032
—
16
37
286
3019
52
182
230
2755
59
319
156
1986
Monocytes [#/volume] in Blood
26484-6 [3001604]
1.0e+00
1.2e+00
1.8e+00
—
1.5e+00
1.3e+00
8.5e-01
cases:24.10%
controls:10.01%
cases:18.24%
controls:6.07%
cases:6.84%
controls:1.21%
—
—
cases:5.96%
controls:1.34%
cases:19.86%
controls:6.23%
cases:28.84%
controls:14.79%
74
307
233
2759
56
186
251
2880
21
37
286
3029
—
18
41
284
3015
56
183
226
2754
62
341
153
1964
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
6.2e-01
1.2e+00
2.3e+00
—
2.0e+00
9.6e-01
6.9e-01
cases:18.89%
controls:11.12%
cases:19.54%
controls:6.78%
cases:6.19%
controls:0.65%
—
—
cases:7.95%
controls:1.15%
cases:18.44%
controls:8.00%
cases:35.81%
controls:21.91%
58
341
249
2725
60
208
247
2858
19
20
288
3046
—
24
35
278
3021
52
235
230
2702
77
505
138
1800
Bacteria identified in Blood by Culture
600-7 [3023368]
8.6e-01
1.5e+00
1.6e+00
—
2.5e+00
1.9e+00
9.6e-01
cases:10.75%
controls:4.83%
cases:10.10%
controls:2.45%
cases:1.95%
controls:0.39%
—
—
cases:3.64%
controls:0.29%
cases:13.83%
controls:2.32%
cases:20.47%
controls:8.98%
33
148
274
2918
31
75
276
2991
6
12
301
3054
—
11
9
291
3047
39
68
243
2869
44
207
171
2098
Basophils [#/volume] in Blood
26444-0 [3006315]
1.0e+00
1.2e+00
1.8e+00
—
1.5e+00
1.3e+00
8.4e-01
cases:24.10%
controls:10.11%
cases:18.24%
controls:6.16%
cases:6.84%
controls:1.21%
—
—
cases:5.96%
controls:1.34%
cases:20.21%
controls:6.23%
cases:28.84%
controls:14.92%
74
310
233
2756
56
189
251
2877
21
37
286
3029
—
18
41
284
3015
57
183
225
2754
62
344
153
1961
Outpatient Hospital
22 [8756]
7.8e-01
9.9e-01
1.3e+00
—
2.2e+00
1.4e+00
1.1e+00
cases:43.97%
controls:26.39%
cases:17.92%
controls:7.50%
cases:4.23%
controls:1.17%
—
—
cases:9.60%
controls:1.18%
cases:20.92%
controls:6.16%
cases:38.14%
controls:17.74%
135
809
172
2257
55
230
252
2836
13
36
294
3030
—
29
36
273
3020
59
181
223
2756
82
409
133
1896
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
8.0e-01
1.2e+00
1.7e+00
—
1.8e+00
1.3e+00
8.3e-01
cases:22.15%
controls:11.32%
cases:18.89%
controls:6.65%
cases:8.14%
controls:1.53%
—
—
cases:6.62%
controls:1.15%
cases:18.79%
controls:5.69%
cases:30.23%
controls:15.92%
68
347
239
2719
58
204
249
2862
25
47
282
3019
—
20
35
282
3021
53
167
229
2770
65
367
150
1938
Eosinophils [#/volume] in Blood
26449-9 [3013115]
1.0e+00
1.2e+00
1.8e+00
—
1.5e+00
1.4e+00
8.0e-01
cases:24.76%
controls:10.44%
cases:18.24%
controls:6.23%
cases:7.17%
controls:1.24%
—
—
cases:5.96%
controls:1.44%
cases:21.28%
controls:6.47%
cases:29.30%
controls:15.70%
76
320
231
2746
56
191
251
2875
22
38
285
3028
—
18
44
284
3012
60
190
222
2747
63
362
152
1943
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5.7e-01
1.2e+00
2.2e+00
—
2.0e+00
9.7e-01
6.8e-01
cases:17.92%
controls:10.96%
cases:19.22%
controls:6.72%
cases:5.86%
controls:0.65%
—
—
cases:7.62%
controls:1.15%
cases:18.44%
controls:7.90%
cases:34.88%
controls:21.30%
55
336
252
2730
59
206
248
2860
18
20
289
3046
—
23
35
279
3021
52
232
230
2705
75
491
140
1814
Bacteria identified in Urine by Culture
630-4 [3026008]
5.6e-01
9.2e-01
2.5e+00
—
2.3e+00
1.2e+00
6.9e-01
cases:13.36%
controls:8.09%
cases:10.75%
controls:4.57%
cases:6.51%
controls:0.55%
—
—
cases:5.63%
controls:0.59%
cases:13.48%
controls:4.66%
cases:25.58%
controls:14.71%
41
248
266
2818
33
140
274
2926
20
17
287
3049
—
17
18
285
3038
38
137
244
2800
55
339
160
1966
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
8.5e-01
1.1e+00
1.5e+00
—
2.2e+00
1.4e+00
6.3e-01
cases:23.45%
controls:11.58%
cases:15.96%
controls:6.10%
cases:5.21%
controls:1.24%
—
—
cases:8.28%
controls:1.01%
cases:21.28%
controls:6.47%
cases:28.84%
controls:17.70%
72
355
235
2711
49
187
258
2879
16
38
291
3028
—
25
31
277
3025
60
190
222
2747
62
408
153
1897
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
2.4e-01
4.0e-01
1.6e+00
3.7e+00
1.8e+00
4.3e-01
1.6e-01
cases:48.53%
controls:42.50%
cases:45.93%
controls:36.37%
cases:29.32%
controls:7.50%
cases:16.94%
controls:0.49%
cases:34.77%
controls:8.31%
cases:47.52%
controls:37.01%
cases:61.40%
controls:57.48%
149
1303
158
1763
141
1115
166
1951
90
230
217
2836
52
15
255
3051
105
254
197
2802
134
1087
148
1850
132
1325
83
980
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
2.4e-01
4.0e-01
1.6e+00
3.7e+00
1.8e+00
4.3e-01
1.6e-01
cases:48.53%
controls:42.50%
cases:45.93%
controls:36.37%
cases:29.32%
controls:7.50%
cases:16.94%
controls:0.49%
cases:34.77%
controls:8.31%
cases:47.52%
controls:37.01%
cases:61.40%
controls:57.48%
149
1303
158
1763
141
1115
166
1951
90
230
217
2836
52
15
255
3051
105
254
197
2802
134
1087
148
1850
132
1325
83
980
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
2.5e-01
3.9e-01
1.6e+00
3.7e+00
1.8e+00
4.3e-01
1.6e-01
cases:48.53%
controls:42.47%
cases:45.93%
controls:36.40%
cases:29.32%
controls:7.50%
cases:16.94%
controls:0.49%
cases:34.77%
controls:8.34%
cases:47.52%
controls:37.04%
cases:61.40%
controls:57.53%
149
1302
158
1764
141
1116
166
1950
90
230
217
2836
52
15
255
3051
105
255
197
2801
134
1088
148
1849
132
1326
83
979
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.4e-01
4.0e-01
1.6e+00
3.7e+00
1.8e+00
4.3e-01
1.9e-01
cases:48.53%
controls:42.56%
cases:45.93%
controls:36.37%
cases:28.99%
controls:7.50%
cases:16.94%
controls:0.49%
cases:35.10%
controls:8.34%
cases:47.52%
controls:37.04%
cases:61.86%
controls:57.40%
149
1305
158
1761
141
1115
166
1951
89
230
218
2836
52
15
255
3051
106
255
196
2801
134
1088
148
1849
133
1323
82
982
MCH [Entitic mass]
28539-5 [3035941]
2.5e-01
4.0e-01
1.6e+00
3.7e+00
1.8e+00
4.3e-01
1.6e-01
cases:48.53%
controls:42.47%
cases:45.93%
controls:36.33%
cases:28.99%
controls:7.47%
cases:16.94%
controls:0.49%
cases:34.77%
controls:8.31%
cases:47.52%
controls:37.01%
cases:61.40%
controls:57.44%
149
1302
158
1764
141
1114
166
1952
89
229
218
2837
52
15
255
3051
105
254
197
2802
134
1087
148
1850
132
1324
83
981
Platelets [#/volume] in Blood
26515-7 [3007461]
2.3e-01
3.9e-01
1.6e+00
3.7e+00
1.8e+00
4.3e-01
1.7e-01
cases:48.21%
controls:42.40%
cases:45.93%
controls:36.40%
cases:28.99%
controls:7.50%
cases:16.94%
controls:0.49%
cases:34.44%
controls:8.28%
cases:47.52%
controls:37.01%
cases:61.40%
controls:57.40%
148
1300
159
1766
141
1116
166
1950
89
230
218
2836
52
15
255
3051
104
253
198
2803
134
1087
148
1850
132
1323
83
982
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
2.4e-01
4.0e-01
1.6e+00
3.7e+00
1.8e+00
4.5e-01
1.6e-01
cases:48.53%
controls:42.50%
cases:45.93%
controls:36.30%
cases:28.66%
controls:7.47%
cases:16.94%
controls:0.49%
cases:34.44%
controls:8.31%
cases:47.87%
controls:37.04%
cases:61.40%
controls:57.44%
149
1303
158
1763
141
1113
166
1953
88
229
219
2837
52
15
255
3051
104
254
198
2802
135
1088
147
1849
132
1324
83
981
Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]
2.0e+00
2.3e+00
—
—
—
3.2e+00
1.4e+00
cases:4.56%
controls:0.62%
cases:3.58%
controls:0.36%
—
—
—
—
—
—
cases:5.32%
controls:0.24%
cases:4.19%
controls:1.04%
14
19
293
3047
11
11
296
3055
—
—
—
15
7
267
2930
9
24
206
2281
Spinal stenosis
M48.0 [45557888]
3.5e+00
—
—
1.0e+50
1.0e+50
—
4.0e+00
cases:5.21%
controls:0.16%
—
—
—
—
cases:3.91%
controls:0.00%
cases:3.31%
controls:0.00%
—
—
cases:10.70%
controls:0.22%
16
5
291
3061
—
—
12
0
295
3066
10
0
292
3056
—
23
5
192
2300
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
5.4e-01
1.2e+00
2.2e+00
—
2.0e+00
9.4e-01
6.5e-01
cases:18.57%
controls:11.74%
cases:19.54%
controls:6.91%
cases:6.19%
controls:0.72%
—
—
cases:7.95%
controls:1.18%
cases:18.44%
controls:8.10%
cases:34.88%
controls:21.78%
57
360
250
2706
60
212
247
2854
19
22
288
3044
—
24
36
278
3020
52
238
230
2699
75
502
140
1803
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
2.4e-01
3.9e-01
1.6e+00
4.1e+00
1.7e+00
4.1e-01
1.2e-01
cases:36.16%
controls:30.79%
cases:31.60%
controls:23.78%
cases:19.54%
controls:4.57%
cases:12.70%
controls:0.23%
cases:23.84%
controls:5.27%
cases:32.62%
controls:24.28%
cases:44.19%
controls:41.26%
111
944
196
2122
97
729
210
2337
60
140
247
2926
39
7
268
3059
72
161
230
2895
92
713
190
2224
95
951
120
1354
calcium (different salts in combination); oral
A12AA20 [21600872]
8.3e-01
1.0e+00
9.7e-01
—
1.4e+00
1.6e+00
1.6e+00
cases:28.01%
controls:14.48%
cases:27.69%
controls:12.26%
cases:10.42%
controls:4.21%
—
—
cases:13.91%
controls:3.70%
cases:43.62%
controls:13.69%
cases:54.42%
controls:18.87%
86
444
221
2622
85
376
222
2690
32
129
275
2937
—
42
113
260
2943
123
402
159
2535
117
435
98
1870
lactulose; oral
A06AD11 [21600571]
5.4e-01
1.0e+00
1.9e+00
—
3.1e+00
1.5e+00
9.2e-01
cases:5.54%
controls:3.29%
cases:4.56%
controls:1.70%
cases:2.28%
controls:0.36%
—
—
cases:4.30%
controls:0.20%
cases:7.45%
controls:1.70%
cases:8.84%
controls:3.73%
17
101
290
2965
14
52
293
3014
7
11
300
3055
—
13
6
289
3050
21
50
261
2887
19
86
196
2219
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.7e-01
4.1e-01
1.6e+00
3.7e+00
1.7e+00
4.2e-01
2.2e-01
cases:47.56%
controls:41.00%
cases:44.63%
controls:34.90%
cases:27.04%
controls:7.01%
cases:16.61%
controls:0.49%
cases:32.45%
controls:7.92%
cases:46.10%
controls:36.09%
cases:61.40%
controls:56.18%
146
1257
161
1809
137
1070
170
1996
83
215
224
2851
51
15
256
3051
98
242
204
2814
130
1060
152
1877
132
1295
83
1010
prednisolone; oral, parenteral
H02AB06 [21602734]
9.9e-01
1.3e+00
1.5e+00
—
1.3e+00
1.3e+00
1.0e+00
cases:24.10%
controls:10.53%
cases:15.96%
controls:4.92%
cases:4.23%
controls:0.98%
—
—
cases:3.97%
controls:1.11%
cases:16.31%
controls:5.01%
cases:28.37%
controls:12.49%
74
323
233
2743
49
151
258
2915
13
30
294
3036
—
12
34
290
3022
46
147
236
2790
61
288
154
2017
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
1.7e+00
2.0e+00
—
—
—
2.3e+00
1.4e+00
cases:3.58%
controls:0.65%
cases:2.61%
controls:0.36%
—
—
—
—
—
—
cases:3.19%
controls:0.34%
cases:4.65%
controls:1.17%
11
20
296
3046
8
11
299
3055
—
—
—
9
10
273
2927
10
27
205
2278
prednisolone
A07EA01 [21600653]
9.8e-01
1.3e+00
1.5e+00
—
1.3e+00
1.3e+00
1.0e+00
cases:24.10%
controls:10.63%
cases:15.96%
controls:4.92%
cases:4.23%
controls:0.98%
—
—
cases:3.97%
controls:1.11%
cases:16.31%
controls:5.01%
cases:28.37%
controls:12.54%
74
326
233
2740
49
151
258
2915
13
30
294
3036
—
12
34
290
3022
46
147
236
2790
61
289
154
2016
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
5.5e-01
1.0e+00
1.9e+00
1.0e+50
2.0e+00
1.2e+00
7.3e-01
cases:28.34%
controls:18.56%
cases:25.41%
controls:10.86%
cases:9.45%
controls:1.50%
cases:3.58%
controls:0.00%
cases:10.93%
controls:1.64%
cases:27.66%
controls:10.73%
cases:42.33%
controls:26.16%
87
569
220
2497
78
333
229
2733
29
46
278
3020
11
0
296
3066
33
50
269
3006
78
315
204
2622
91
603
124
1702
pH of Urine
2756-5 [3015736]
7.4e-01
1.1e+00
1.8e+00
—
1.9e+00
1.1e+00
7.0e-01
cases:16.94%
controls:8.84%
cases:13.68%
controls:4.83%
cases:3.26%
controls:0.55%
—
—
cases:5.96%
controls:0.92%
cases:15.25%
controls:5.86%
cases:28.37%
controls:16.40%
52
271
255
2795
42
148
265
2918
10
17
297
3049
—
18
28
284
3028
43
172
239
2765
61
378
154
1927
Physiotherapy
R4110 [2001310233]
7.6e-01
1.4e+00
1.9e+00
1.0e+50
2.8e+00
2.3e+00
7.8e-01
cases:11.07%
controls:5.48%
cases:6.19%
controls:1.57%
cases:1.95%
controls:0.29%
cases:4.56%
controls:0.00%
cases:4.30%
controls:0.26%
cases:12.06%
controls:1.33%
cases:11.16%
controls:5.47%
34
168
273
2898
19
48
288
3018
6
9
301
3057
14
0
293
3066
13
8
289
3048
34
39
248
2898
24
126
191
2179
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6.8e-01
1.0e+00
1.7e+00
—
2.0e+00
1.1e+00
8.1e-01
cases:35.18%
controls:21.56%
cases:28.66%
controls:12.82%
cases:14.01%
controls:2.77%
—
—
cases:15.56%
controls:2.36%
cases:31.21%
controls:13.45%
cases:46.51%
controls:27.81%
108
661
199
2405
88
393
219
2673
43
85
264
2981
—
47
72
255
2984
88
395
194
2542
100
641
115
1664
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.1e+00
1.6e+00
2.3e+00
—
2.5e+00
1.9e+00
8.0e-01
cases:10.10%
controls:3.49%
cases:6.19%
controls:1.27%
cases:1.63%
controls:0.16%
—
—
cases:2.65%
controls:0.23%
cases:8.87%
controls:1.43%
cases:9.77%
controls:4.64%
31
107
276
2959
19
39
288
3027
5
5
302
3061
—
8
7
294
3049
25
42
257
2895
21
107
194
2198
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1.0e+00
1.1e+00
1.8e+00
—
2.1e+00
1.1e+00
5.4e-01
cases:14.66%
controls:5.74%
cases:7.17%
controls:2.45%
cases:2.61%
controls:0.46%
—
—
cases:2.98%
controls:0.36%
cases:6.03%
controls:2.15%
cases:14.88%
controls:9.24%
45
176
262
2890
22
75
285
2991
8
14
299
3052
—
9
11
293
3045
17
63
265
2874
32
213
183
2092
Emergency Room and Inpatient Visit
ERIP [262]
7.5e-01
1.4e+00
1.3e+00
—
2.9e+00
1.3e+00
6.9e-01
cases:12.38%
controls:6.26%
cases:12.70%
controls:3.46%
cases:1.95%
controls:0.55%
—
—
cases:5.30%
controls:0.29%
cases:14.89%
controls:4.36%
cases:22.79%
controls:12.93%
38
192
269
2874
39
106
268
2960
6
17
301
3049
—
16
9
286
3047
42
128
240
2809
49
298
166
2007
Office Visit
OMOP4822458 [581477]
9.1e-01
1.3e+00
1.9e+00
—
2.1e+00
1.8e+00
9.9e-01
cases:18.24%
controls:8.25%
cases:8.14%
controls:2.28%
cases:1.95%
controls:0.29%
—
—
cases:3.97%
controls:0.52%
cases:10.64%
controls:1.91%
cases:16.74%
controls:6.94%
56
253
251
2813
25
70
282
2996
6
9
301
3057
—
12
16
290
3040
30
56
252
2881
36
160
179
2145
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
8.5e-01
1.2e+00
1.6e+00
—
1.3e+00
1.3e+00
8.1e-01
cases:26.06%
controls:13.05%
cases:20.52%
controls:7.44%
cases:8.79%
controls:1.89%
—
—
cases:7.62%
controls:2.16%
cases:23.05%
controls:7.59%
cases:32.56%
controls:17.61%
80
400
227
2666
63
228
244
2838
27
58
280
3008
—
23
66
279
2990
65
223
217
2714
70
406
145
1899
Unspecified osteoporosis with pathological fracture
M80.9 [45553292]
2.3e+00
—
—
1.0e+50
—
3.9e+00
3.2e+00
cases:1.63%
controls:0.16%
—
—
—
—
cases:1.95%
controls:0.00%
—
—
cases:7.45%
controls:0.17%
cases:6.05%
controls:0.26%
5
5
302
3061
—
—
6
0
301
3066
—
21
5
261
2932
13
6
202
2299
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
6.7e-01
9.0e-01
1.3e+00
—
1.7e+00
1.3e+00
1.0e+00
cases:54.72%
controls:38.13%
cases:41.37%
controls:22.21%
cases:16.61%
controls:5.06%
—
—
cases:23.18%
controls:5.14%
cases:53.19%
controls:22.95%
cases:71.16%
controls:46.68%
168
1169
139
1897
127
681
180
2385
51
155
256
2911
—
70
157
232
2899
150
674
132
2263
153
1076
62
1229
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
1.2e+00
1.4e+00
2.1e+00
—
1.8e+00
1.4e+00
1.1e+00
cases:7.82%
controls:2.58%
cases:6.19%
controls:1.53%
cases:1.63%
controls:0.20%
—
—
cases:2.32%
controls:0.39%
cases:7.80%
controls:2.04%
cases:13.95%
controls:5.16%
24
79
283
2987
19
47
288
3019
5
6
302
3060
—
7
12
295
3044
22
60
260
2877
30
119
185
2186
oxycodone and naloxone; oral
N02AA55 [21604265]
7.3e-01
2.2e+00
—
—
—
3.1e+00
1.4e+00
cases:3.58%
controls:1.76%
cases:5.86%
controls:0.65%
—
—
—
—
—
—
cases:13.12%
controls:0.68%
cases:12.09%
controls:3.21%
11
54
296
3012
18
20
289
3046
—
—
—
37
20
245
2917
26
74
189
2231
pantoprazole; oral, parenteral
A02BC02 [21600097]
8.0e-01
1.2e+00
1.1e+00
—
1.5e+00
1.2e+00
9.1e-01
cases:34.20%
controls:18.92%
cases:29.32%
controls:11.38%
cases:9.12%
controls:3.20%
—
—
cases:11.59%
controls:2.85%
cases:32.27%
controls:12.36%
cases:41.86%
controls:22.52%
105
580
202
2486
90
349
217
2717
28
98
279
2968
—
35
87
267
2969
91
363
191
2574
90
519
125
1786
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
1.4e+00
2.1e+00
—
—
—
1.8e+00
1.4e+00
cases:3.26%
controls:0.82%
cases:4.56%
controls:0.59%
—
—
—
—
—
—
cases:2.48%
controls:0.41%
cases:4.65%
controls:1.21%
10
25
297
3041
14
18
293
3048
—
—
—
7
12
275
2925
10
28
205
2277
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
1.0e+00
1.5e+00
2.1e+00
—
1.8e+00
1.4e+00
9.9e-01
cases:7.82%
controls:2.90%
cases:6.84%
controls:1.66%
cases:1.63%
controls:0.20%
—
—
cases:2.32%
controls:0.39%
cases:8.16%
controls:2.15%
cases:14.42%
controls:5.90%
24
89
283
2977
21
51
286
3015
5
6
302
3060
—
7
12
295
3044
23
63
259
2874
31
136
184
2169
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
9.1e-01
1.3e+00
2.3e+00
—
2.1e+00
1.3e+00
8.1e-01
cases:12.38%
controls:5.38%
cases:9.45%
controls:2.77%
cases:2.93%
controls:0.29%
—
—
cases:1.66%
controls:0.20%
cases:8.87%
controls:2.52%
cases:18.14%
controls:8.98%
38
165
269
2901
29
85
278
2981
9
9
298
3057
—
5
6
297
3050
25
74
257
2863
39
207
176
2098
Pharmacy visit
OMOP4822462 [581458]
1.1e+00
1.7e+00
1.0e+00
1.7e+00
1.1e+00
1.2e+00
1.0e+50
cases:98.70%
controls:96.02%
cases:98.05%
controls:90.15%
cases:79.15%
controls:57.83%
cases:14.01%
controls:3.00%
cases:80.46%
controls:57.62%
cases:96.81%
controls:90.47%
cases:100.00%
controls:97.05%
303
2944
4
122
301
2764
6
302
243
1773
64
1293
43
92
264
2974
243
1761
59
1295
273
2657
9
280
215
2237
0
68
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.1e+00
1.2e+00
2.5e+00
—
1.6e+00
1.8e+00
6.8e-01
cases:7.82%
controls:2.64%
cases:4.89%
controls:1.50%
cases:2.61%
controls:0.23%
—
—
cases:2.32%
controls:0.46%
cases:9.57%
controls:1.67%
cases:7.91%
controls:4.16%
24
81
283
2985
15
46
292
3020
8
7
299
3059
—
7
14
295
3042
27
49
255
2888
17
96
198
2209
alendronic acid; oral
M05BA04 [21604152]
1.1e+00
6.5e-01
1.5e+00
—
1.8e+00
2.1e+00
1.6e+00
cases:7.17%
controls:2.45%
cases:3.26%
controls:1.73%
cases:2.28%
controls:0.52%
—
—
cases:3.64%
controls:0.62%
cases:12.06%
controls:1.67%
cases:12.09%
controls:2.69%
22
75
285
2991
10
53
297
3013
7
16
300
3050
—
11
19
291
3037
34
49
248
2888
26
62
189
2243
Postmenopausal osteoporosis with pathological fracture
M80.0 [45572553]
—
2.1e+00
—
—
—
3.6e+00
3.0e+00
—
—
cases:1.63%
controls:0.20%
—
—
—
—
—
—
cases:6.74%
controls:0.20%
cases:9.77%
controls:0.52%
—
5
6
302
3060
—
—
—
19
6
263
2931
21
12
194
2293
Normoblasts [#/volume] in Blood
715-3 [3021589]
9.0e-01
1.0e+00
1.9e+00
—
1.7e+00
9.6e-01
4.7e-01
cases:20.52%
controls:9.46%
cases:17.59%
controls:7.18%
cases:10.10%
controls:1.66%
—
—
cases:8.94%
controls:1.73%
cases:18.44%
controls:8.00%
cases:23.72%
controls:16.31%
63
290
244
2776
54
220
253
2846
31
51
276
3015
—
27
53
275
3003
52
235
230
2702
51
376
164
1929
hydroxychloroquine; oral
P01BA02 [21604889]
1.5e+00
1.8e+00
—
—
2.0e+00
1.8e+00
1.4e+00
cases:5.54%
controls:1.34%
cases:4.89%
controls:0.85%
—
—
—
—
cases:1.66%
controls:0.23%
cases:4.96%
controls:0.89%
cases:5.58%
controls:1.39%
17
41
290
3025
15
26
292
3040
—
—
5
7
297
3049
14
26
268
2911
12
32
203
2273
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
1.5e+00
2.3e+00
—
—
—
2.6e+00
7.4e-01
cases:2.93%
controls:0.65%
cases:2.28%
controls:0.23%
—
—
—
—
—
—
cases:3.55%
controls:0.27%
cases:2.79%
controls:1.34%
9
20
298
3046
7
7
300
3059
—
—
—
10
8
272
2929
6
31
209
2274
tizanidine; oral
M03BX02 [21604116]
9.3e-01
1.7e+00
2.9e+00
—
—
8.9e-01
8.6e-01
cases:16.29%
controls:7.11%
cases:11.40%
controls:2.22%
cases:4.89%
controls:0.29%
—
—
—
—
cases:5.32%
controls:2.25%
cases:11.63%
controls:5.29%
50
218
257
2848
35
68
272
2998
15
9
292
3057
—
—
15
66
267
2871
25
122
190
2183
Pulmonary Disease
29 [38004472]
8.3e-01
1.3e+00
2.0e+00
—
1.4e+00
1.3e+00
1.0e+00
cases:18.57%
controls:9.00%
cases:13.36%
controls:4.08%
cases:3.58%
controls:0.52%
—
—
cases:2.98%
controls:0.75%
cases:13.12%
controls:3.98%
cases:20.00%
controls:8.37%
57
276
250
2790
41
125
266
2941
11
16
296
3050
—
9
23
293
3033
37
117
245
2820
43
193
172
2112
clindamycin; oral, parenteral
J01FF01 [21602985]
9.9e-01
1.7e+00
—
—
—
2.1e+00
1.6e+00
cases:8.14%
controls:3.20%
cases:3.26%
controls:0.62%
—
—
—
—
—
—
cases:3.55%
controls:0.44%
cases:11.16%
controls:2.52%
25
98
282
2968
10
19
297
3047
—
—
—
10
13
272
2924
24
58
191
2247
Inpatient Visit
IP [9201]
4.0e-01
1.3e+00
1.6e+00
1.0e+50
2.6e+00
1.8e+00
7.7e-01
cases:8.79%
controls:6.07%
cases:9.45%
controls:2.87%
cases:1.63%
controls:0.33%
cases:3.58%
controls:0.00%
cases:5.30%
controls:0.43%
cases:14.89%
controls:2.93%
cases:19.53%
controls:10.11%
27
186
280
2880
29
88
278
2978
5
10
302
3056
11
0
296
3066
16
13
286
3043
42
86
240
2851
42
233
173
2072
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
1.8e+00
2.1e+00
—
—
—
2.5e+00
—
cases:4.23%
controls:0.72%
cases:2.28%
controls:0.29%
—
—
—
—
—
—
cases:3.55%
controls:0.31%
—
—
13
22
294
3044
7
9
300
3057
—
—
—
10
9
272
2928
—
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
8.2e-01
9.3e-01
—
—
2.4e+00
1.3e+00
7.7e-01
cases:12.38%
controls:5.87%
cases:7.49%
controls:3.10%
—
—
—
—
cases:3.64%
controls:0.33%
cases:12.06%
controls:3.44%
cases:19.07%
controls:9.80%
38
180
269
2886
23
95
284
2971
—
—
11
10
291
3046
34
101
248
2836
41
226
174
2079
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
3.9e-01
1.2e+00
1.9e+00
1.0e+50
2.1e+00
1.2e+00
4.1e-01
cases:20.85%
controls:15.13%
cases:18.89%
controls:6.72%
cases:6.19%
controls:1.01%
cases:2.61%
controls:0.00%
cases:5.63%
controls:0.75%
cases:20.92%
controls:7.32%
cases:28.84%
controls:21.26%
64
464
243
2602
58
206
249
2860
19
31
288
3035
8
0
299
3066
17
23
285
3033
59
215
223
2722
62
490
153
1815
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
1.4e+00
1.8e+00
—
—
—
1.8e+00
1.2e+00
cases:6.84%
controls:1.73%
cases:5.21%
controls:0.88%
—
—
—
—
—
—
cases:3.19%
controls:0.54%
cases:9.30%
controls:2.91%
21
53
286
3013
16
27
291
3039
—
—
—
9
16
273
2921
20
67
195
2238
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
9.8e-01
1.5e+00
2.3e+00
—
2.1e+00
1.5e+00
6.0e-01
cases:6.51%
controls:2.54%
cases:4.23%
controls:0.98%
cases:2.28%
controls:0.23%
—
—
cases:1.66%
controls:0.20%
cases:5.32%
controls:1.29%
cases:8.37%
controls:4.77%
20
78
287
2988
13
30
294
3036
7
7
300
3059
—
5
6
297
3050
15
38
267
2899
18
110
197
2195
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
7.0e-01
1.1e+00
1.5e+00
—
2.3e+00
1.4e+00
7.3e-01
cases:15.64%
controls:8.45%
cases:11.07%
controls:3.91%
cases:2.61%
controls:0.62%
—
—
cases:3.97%
controls:0.43%
cases:14.89%
controls:4.02%
cases:23.72%
controls:13.06%
48
259
259
2807
34
120
273
2946
8
19
299
3047
—
12
13
290
3043
42
118
240
2819
51
301
164
2004
Pneumonia, unspecified
J18.9 [45601123]
1.1e+00
9.6e-01
2.7e+00
—
—
1.6e+00
9.0e-01
cases:10.75%
controls:3.98%
cases:4.56%
controls:1.79%
cases:2.28%
controls:0.16%
—
—
—
—
cases:7.09%
controls:1.50%
cases:15.81%
controls:7.07%
33
122
274
2944
14
55
293
3011
7
5
300
3061
—
—
20
44
262
2893
34
163
181
2142
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
8.2e-01
1.5e+00
1.8e+00
—
2.6e+00
1.3e+00
3.9e-01
cases:10.42%
controls:4.89%
cases:9.45%
controls:2.25%
cases:1.95%
controls:0.33%
—
—
cases:2.98%
controls:0.23%
cases:9.57%
controls:2.76%
cases:12.09%
controls:8.50%
32
150
275
2916
29
69
278
2997
6
10
301
3056
—
9
7
293
3049
27
81
255
2856
26
196
189
2109
methotrexate; oral, parenteral
L04AX03 [21603929]
1.7e+00
1.5e+00
—
—
1.8e+00
1.3e+00
1.1e+00
cases:7.17%
controls:1.44%
cases:5.54%
controls:1.30%
—
—
—
—
cases:2.65%
controls:0.46%
cases:4.61%
controls:1.33%
cases:5.12%
controls:1.69%
22
44
285
3022
17
40
290
3026
—
—
8
14
294
3042
13
39
269
2898
11
39
204
2266
methotrexate
L01BA01 [21601423]
1.7e+00
1.5e+00
—
—
1.8e+00
1.3e+00
1.1e+00
cases:7.17%
controls:1.44%
cases:5.54%
controls:1.30%
—
—
—
—
cases:2.65%
controls:0.46%
cases:4.61%
controls:1.33%
cases:5.12%
controls:1.69%
22
44
285
3022
17
40
290
3026
—
—
8
14
294
3042
13
39
269
2898
11
39
204
2266
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
1.3e+00
2.1e+00
—
1.0e+50
—
1.9e+00
9.3e-01
cases:5.21%
controls:1.50%
cases:4.23%
controls:0.55%
—
—
cases:1.63%
controls:0.00%
—
—
cases:6.38%
controls:1.02%
cases:9.30%
controls:3.90%
16
46
291
3020
13
17
294
3049
—
5
0
302
3066
—
18
30
264
2907
20
90
195
2215
Infectious Disease
44 [38004484]
1.2e+00
2.1e+00
—
—
—
1.4e+00
1.4e+00
cases:4.89%
controls:1.50%
cases:3.91%
controls:0.49%
—
—
—
—
—
—
cases:3.55%
controls:0.89%
cases:6.98%
controls:1.78%
15
46
292
3020
12
15
295
3051
—
—
—
10
26
272
2911
15
41
200
2264
Depressive episode, unspecified
F32.9 [45571760]
1.5e+00
2.3e+00
—
—
—
2.4e+00
1.3e+00
cases:3.58%
controls:0.85%
cases:2.93%
controls:0.29%
—
—
—
—
—
—
cases:2.13%
controls:0.20%
cases:3.26%
controls:0.87%
11
26
296
3040
9
9
298
3057
—
—
—
6
6
276
2931
7
20
208
2285
Respiratory and circulatory monitoring
WX700 [2001310817]
1.1e+00
1.8e+00
—
—
—
2.1e+00
1.2e+00
cases:6.84%
controls:2.32%
cases:2.61%
controls:0.46%
—
—
—
—
—
—
cases:5.32%
controls:0.68%
cases:7.91%
controls:2.65%
21
71
286
2995
8
14
299
3052
—
—
—
15
20
267
2917
17
61
198
2244
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
1.4e+00
2.2e+00
—
—
—
2.1e+00
1.9e+00
cases:2.28%
controls:0.55%
cases:3.58%
controls:0.42%
—
—
—
—
—
—
cases:3.19%
controls:0.41%
cases:4.65%
controls:0.74%
7
17
300
3049
11
13
296
3053
—
—
—
9
12
273
2925
10
17
205
2288
Limited function/disability (L)
L28 [2002000647]
4.1e-01
8.5e-01
1.9e+00
—
2.2e+00
2.0e+00
6.6e-01
cases:4.23%
controls:2.84%
cases:4.23%
controls:1.86%
cases:3.26%
controls:0.49%
—
—
cases:3.64%
controls:0.43%
cases:12.06%
controls:1.80%
cases:12.56%
controls:6.90%
13
87
294
2979
13
57
294
3009
10
15
297
3051
—
11
13
291
3043
34
53
248
2884
27
159
188
2146
Laboratory Visit
OMOP4822461 [32036]
1.8e-01
2.6e-01
1.2e+00
3.5e+00
1.4e+00
3.0e-01
1.8e-01
cases:50.49%
controls:45.89%
cases:49.51%
controls:42.95%
cases:34.53%
controls:13.76%
cases:20.85%
controls:0.78%
cases:39.40%
controls:13.81%
cases:51.42%
controls:43.92%
cases:65.12%
controls:60.95%
155
1407
152
1659
152
1317
155
1749
106
422
201
2644
64
24
243
3042
119
422
183
2634
145
1290
137
1647
140
1405
75
900
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
1.5e+00
2.5e+00
—
—
—
2.1e+00
1.0e+00
cases:3.91%
controls:0.88%
cases:2.61%
controls:0.23%
—
—
—
—
—
—
cases:3.55%
controls:0.44%
cases:4.65%
controls:1.69%
12
27
295
3039
8
7
299
3059
—
—
—
10
13
272
2924
10
39
205
2266
Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis
50796-2 [3029338]
2.0e+00
2.4e+00
—
—
—
—
1.7e+00
cases:3.91%
controls:0.55%
cases:2.93%
controls:0.26%
—
—
—
—
—
—
—
—
cases:4.19%
controls:0.82%
12
17
295
3049
9
8
298
3058
—
—
—
—
9
19
206
2286
Neurosurgery
14 [38004459]
9.6e-01
1.5e+00
—
1.0e+50
—
2.8e+00
1.7e+00
cases:3.91%
controls:1.53%
cases:3.58%
controls:0.78%
—
—
cases:1.95%
controls:0.00%
—
—
cases:8.51%
controls:0.54%
cases:6.05%
controls:1.17%
12
47
295
3019
11
24
296
3042
—
6
0
301
3066
—
24
16
258
2921
13
27
202
2278
CBC panel - Blood by Automated count
58410-2 [40761511]
3.1e-01
4.1e-01
1.3e+00
3.2e+00
1.5e+00
2.7e-01
6.1e-02
cases:43.32%
controls:35.81%
cases:32.57%
controls:24.36%
cases:15.31%
controls:4.50%
cases:8.79%
controls:0.39%
cases:19.54%
controls:5.04%
cases:29.43%
controls:24.21%
cases:46.51%
controls:44.99%
133
1098
174
1968
100
747
207
2319
47
138
260
2928
27
12
280
3054
59
154
243
2902
83
711
199
2226
100
1037
115
1268
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
6.7e-01
9.9e-01
1.6e+00
—
1.7e+00
1.1e+00
4.4e-01
cases:31.60%
controls:19.11%
cases:22.80%
controls:9.85%
cases:7.49%
controls:1.53%
—
—
cases:8.94%
controls:1.80%
cases:23.76%
controls:9.74%
cases:35.35%
controls:26.03%
97
586
210
2480
70
302
237
2764
23
47
284
3019
—
27
55
275
3001
67
286
215
2651
76
600
139
1705
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
1.4e+00
1.9e+00
—
1.0e+50
—
1.8e+00
1.0e+00
cases:5.21%
controls:1.40%
cases:3.91%
controls:0.62%
—
—
cases:1.63%
controls:0.00%
—
—
cases:6.38%
controls:1.09%
cases:10.70%
controls:4.21%
16
43
291
3023
12
19
295
3047
—
5
0
302
3066
—
18
32
264
2905
23
97
192
2208
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
1.6e+00
2.2e+00
—
—
—
2.2e+00
1.0e+00
cases:3.91%
controls:0.78%
cases:2.61%
controls:0.29%
—
—
—
—
—
—
cases:3.55%
controls:0.41%
cases:4.65%
controls:1.74%
12
24
295
3042
8
9
299
3057
—
—
—
10
12
272
2925
10
40
205
2265
Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Electrophoresis
35559-4 [3035797]
2.0e+00
2.4e+00
—
—
—
—
1.6e+00
cases:4.56%
controls:0.65%
cases:3.26%
controls:0.29%
—
—
—
—
—
—
—
—
cases:4.19%
controls:0.87%
14
20
293
3046
10
9
297
3057
—
—
—
—
9
20
206
2285
Supplier / Service Provider
OMOP5117446 [33004]
-1.1e-01
1.6e-02
—
—
—
2.7e+00
3.3e+00
cases:20.85%
controls:22.77%
cases:5.86%
controls:5.77%
—
—
—
—
—
—
cases:7.09%
controls:0.51%
cases:16.74%
controls:0.74%
64
698
243
2368
18
177
289
2889
—
—
—
20
15
262
2922
36
17
179
2288
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1.7e+00
2.2e+00
—
—
—
2.1e+00
6.9e-01
cases:3.91%
controls:0.75%
cases:3.58%
controls:0.42%
—
—
—
—
—
—
cases:5.32%
controls:0.68%
cases:3.72%
controls:1.91%
12
23
295
3043
11
13
296
3053
—
—
—
15
20
267
2917
8
44
207
2261
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
1.0e+00
1.7e+00
—
—
—
2.1e+00
1.1e+00
cases:7.82%
controls:2.94%
cases:6.19%
controls:1.14%
—
—
—
—
—
—
cases:7.09%
controls:0.95%
cases:10.23%
controls:3.77%
24
90
283
2976
19
35
288
3031
—
—
—
20
28
262
2909
22
87
193
2218
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
3.1e-01
1.0e+00
2.3e+00
—
1.9e+00
7.2e-01
5.0e-01
cases:13.03%
controls:9.92%
cases:14.01%
controls:5.51%
cases:5.21%
controls:0.55%
—
—
cases:5.63%
controls:0.92%
cases:12.06%
controls:6.23%
cases:25.12%
controls:16.92%
40
304
267
2762
43
169
264
2897
16
17
291
3049
—
17
28
285
3028
34
183
248
2754
54
390
161
1915
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.8e-01
4.3e-01
1.3e+00
2.4e+00
1.2e+00
5.1e-01
2.4e-01
cases:44.63%
controls:37.87%
cases:38.44%
controls:28.93%
cases:16.29%
controls:5.02%
cases:2.93%
controls:0.26%
cases:15.56%
controls:5.24%
cases:41.84%
controls:30.17%
cases:58.14%
controls:52.15%
137
1161
170
1905
118
887
189
2179
50
154
257
2912
9
8
298
3058
47
160
255
2896
118
886
164
2051
125
1202
90
1103
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
1.4e+00
2.3e+00
—
—
—
2.1e+00
9.7e-01
cases:3.58%
controls:0.88%
cases:2.61%
controls:0.26%
—
—
—
—
—
—
cases:3.55%
controls:0.44%
cases:4.65%
controls:1.82%
11
27
296
3039
8
8
299
3058
—
—
—
10
13
272
2924
10
42
205
2263
Neurology
13 [38004458]
8.1e-01
1.0e+00
1.4e+00
—
1.8e+00
1.4e+00
7.9e-01
cases:21.82%
controls:11.06%
cases:9.45%
controls:3.69%
cases:2.93%
controls:0.75%
—
—
cases:3.31%
controls:0.59%
cases:13.83%
controls:3.71%
cases:19.07%
controls:9.67%
67
339
240
2727
29
113
278
2953
9
23
298
3043
—
10
18
292
3038
39
109
243
2828
41
223
174
2082
Case Management Agency
251B00000X [38004193]
2.0e-01
3.4e-01
1.2e+00
3.6e+00
9.4e-01
4.5e-01
2.5e-01
cases:71.01%
controls:66.67%
cases:68.40%
controls:60.76%
cases:51.79%
controls:24.49%
cases:35.18%
controls:1.44%
cases:44.37%
controls:23.79%
cases:74.11%
controls:64.62%
cases:86.05%
controls:82.73%
218
2044
89
1022
210
1863
97
1203
159
751
148
2315
108
44
199
3022
134
727
168
2329
209
1898
73
1039
185
1907
30
398
esomeprazole; oral, parenteral
A02BC05 [21600100]
9.4e-01
1.3e+00
1.3e+00
—
1.2e+00
1.2e+00
1.0e+00
cases:19.54%
controls:8.68%
cases:13.68%
controls:4.31%
cases:3.91%
controls:1.08%
—
—
cases:2.98%
controls:0.95%
cases:12.41%
controls:4.02%
cases:19.07%
controls:7.94%
60
266
247
2800
42
132
265
2934
12
33
295
3033
—
9
29
293
3027
35
118
247
2819
41
183
174
2122
Gas panel - Venous blood
24339-4 [3000991]
1.6e+00
2.1e+00
—
—
—
2.0e+00
4.4e-01
cases:6.51%
controls:1.34%
cases:3.58%
controls:0.46%
—
—
—
—
—
—
cases:5.67%
controls:0.82%
cases:4.65%
controls:3.04%
20
41
287
3025
11
14
296
3052
—
—
—
16
24
266
2913
10
70
205
2235
Nephrology
39 [38004479]
1.3e+00
1.8e+00
—
—
2.5e+00
1.4e+00
5.3e-01
cases:3.58%
controls:1.04%
cases:3.58%
controls:0.62%
—
—
—
—
cases:2.32%
controls:0.20%
cases:3.55%
controls:0.89%
cases:2.33%
controls:1.39%
11
32
296
3034
11
19
296
3047
—
—
7
6
295
3050
10
26
272
2911
5
32
210
2273
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
4.5e-01
1.0e+00
1.7e+00
—
1.5e+00
9.1e-01
5.8e-01
cases:27.36%
controls:19.44%
cases:24.10%
controls:10.31%
cases:6.84%
controls:1.34%
—
—
cases:7.62%
controls:1.87%
cases:23.40%
controls:10.93%
cases:40.00%
controls:27.20%
84
596
223
2470
74
316
233
2750
21
41
286
3025
—
23
57
279
2999
66
321
216
2616
86
627
129
1678
denosumab; parenteral
M05BX04 [21604169]
7.9e-01
1.4e+00
—
—
—
2.3e+00
1.9e+00
cases:2.28%
controls:1.04%
cases:3.26%
controls:0.82%
—
—
—
—
—
—
cases:9.93%
controls:1.09%
cases:13.49%
controls:2.26%
7
32
300
3034
10
25
297
3041
—
—
—
28
32
254
2905
29
52
186
2253
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
2.2e+00
—
1.0e+50
1.0e+50
1.0e+50
—
3.4e+00
cases:5.54%
controls:0.62%
—
—
cases:3.91%
controls:0.00%
cases:9.12%
controls:0.00%
cases:3.31%
controls:0.00%
—
—
cases:9.30%
controls:0.35%
17
19
290
3047
—
12
0
295
3066
28
0
279
3066
10
0
292
3056
—
20
8
195
2297
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
7.6e-01
1.1e+00
1.6e+00
—
1.8e+00
1.2e+00
7.0e-01
cases:16.29%
controls:8.35%
cases:12.38%
controls:4.47%
cases:2.28%
controls:0.49%
—
—
cases:4.64%
controls:0.79%
cases:15.60%
controls:5.21%
cases:26.05%
controls:14.92%
50
256
257
2810
38
137
269
2929
7
15
300
3051
—
14
24
288
3032
44
153
238
2784
56
344
159
1961
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
1.0e+00
1.6e+00
2.1e+00
—
—
1.9e+00
1.1e+00
cases:6.84%
controls:2.61%
cases:6.19%
controls:1.34%
cases:1.63%
controls:0.20%
—
—
—
—
cases:6.03%
controls:0.99%
cases:12.09%
controls:4.38%
21
80
286
2986
19
41
288
3025
5
6
302
3060
—
—
17
29
265
2908
26
101
189
2204
amitriptyline; oral, parenteral
N06AA09 [21604696]
1.2e+00
1.7e+00
—
—
—
1.6e+00
1.0e+00
cases:8.14%
controls:2.54%
cases:4.56%
controls:0.88%
—
—
—
—
—
—
cases:4.96%
controls:1.09%
cases:6.51%
controls:2.39%
25
78
282
2988
14
27
293
3039
—
—
—
14
32
268
2905
14
55
201
2250
Other and unspecified abdominal pain
R10.4 [45568113]
9.8e-01
1.5e+00
—
1.0e+50
—
1.9e+00
1.1e+00
cases:12.05%
controls:4.89%
cases:6.84%
controls:1.63%
—
—
cases:1.95%
controls:0.00%
—
—
cases:8.51%
controls:1.40%
cases:14.88%
controls:5.25%
37
150
270
2916
21
50
286
3016
—
6
0
301
3066
—
24
41
258
2896
32
121
183
2184
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
1.6e+00
2.0e+00
—
—
—
1.9e+00
3.9e-01
cases:3.91%
controls:0.85%
cases:1.95%
controls:0.26%
—
—
—
—
—
—
cases:3.55%
controls:0.54%
cases:2.79%
controls:1.91%
12
26
295
3040
6
8
301
3058
—
—
—
10
16
272
2921
6
44
209
2261
Abdominal CT examination
JN3AD [2001305554]
1.6e+00
2.1e+00
—
—
—
1.8e+00
9.7e-01
cases:3.58%
controls:0.75%
cases:2.93%
controls:0.36%
—
—
—
—
—
—
cases:4.26%
controls:0.75%
cases:4.65%
controls:1.82%
11
23
296
3043
9
11
298
3055
—
—
—
12
22
270
2915
10
42
205
2263
Psychiatry
26 [38004469]
9.1e-01
1.5e+00
—
—
—
1.7e+00
1.4e+00
cases:6.84%
controls:2.87%
cases:5.21%
controls:1.24%
—
—
—
—
—
—
cases:6.74%
controls:1.26%
cases:10.23%
controls:2.82%
21
88
286
2978
16
38
291
3028
—
—
—
19
37
263
2900
22
65
193
2240
Rheumatology
66 [38004491]
1.6e+00
1.2e+00
—
—
—
1.6e+00
1.1e+00
cases:11.07%
controls:2.51%
cases:4.56%
controls:1.37%
—
—
—
—
—
—
cases:6.38%
controls:1.36%
cases:7.44%
controls:2.69%
34
77
273
2989
14
42
293
3024
—
—
—
18
40
264
2897
16
62
199
2243
Fever, unspecified
R50.9 [45582716]
1.6e+00
1.2e+00
—
—
—
2.4e+00
1.5e+00
cases:4.56%
controls:0.95%
cases:1.63%
controls:0.49%
—
—
—
—
—
—
cases:2.84%
controls:0.27%
cases:7.44%
controls:1.78%
14
29
293
3037
5
15
302
3051
—
—
—
8
8
274
2929
16
41
199
2264
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
2.0e-01
8.7e-01
1.6e+00
—
2.5e+00
1.4e+00
7.0e-01
cases:11.73%
controls:9.85%
cases:9.12%
controls:4.04%
cases:2.61%
controls:0.55%
—
—
cases:4.97%
controls:0.43%
cases:13.83%
controls:3.98%
cases:20.93%
controls:11.58%
36
302
271
2764
28
124
279
2942
8
17
299
3049
—
15
13
287
3043
39
117
243
2820
45
267
170
2038
Lumbago with sciatica
M54.4 [45553205]
1.7e+00
3.7e+00
—
1.0e+50
—
—
1.3e+00
cases:3.26%
controls:0.59%
cases:7.17%
controls:0.20%
—
—
cases:1.63%
controls:0.00%
—
—
—
—
cases:3.72%
controls:1.00%
10
18
297
3048
22
6
285
3060
—
5
0
302
3066
—
—
8
23
207
2282
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
1.3e+00
2.0e+00
—
—
—
2.1e+00
8.1e-01
cases:4.23%
controls:1.17%
cases:2.93%
controls:0.39%
—
—
—
—
—
—
cases:5.32%
controls:0.72%
cases:5.58%
controls:2.56%
13
36
294
3030
9
12
298
3054
—
—
—
15
21
267
2916
12
59
203
2246
macrogol; oral
A06AD15 [21600575]
3.1e-01
1.7e+00
—
—
2.7e+00
1.1e+00
9.0e-01
cases:1.95%
controls:1.44%
cases:4.89%
controls:0.91%
—
—
—
—
cases:2.98%
controls:0.20%
cases:3.55%
controls:1.26%
cases:9.30%
controls:3.99%
6
44
301
3022
15
28
292
3038
—
—
9
6
293
3050
10
37
272
2900
20
92
195
2213
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
9.6e-01
1.4e+00
—
—
2.5e+00
1.4e+00
8.3e-01
cases:4.23%
controls:1.66%
cases:4.56%
controls:1.11%
—
—
—
—
cases:1.99%
controls:0.16%
cases:4.61%
controls:1.23%
cases:6.98%
controls:3.17%
13
51
294
3015
14
34
293
3032
—
—
6
5
296
3051
13
36
269
2901
15
73
200
2232
X-ray examination of the lungs in one projection
GD1PA [2001303645]
8.9e-01
2.1e+00
—
—
—
1.9e+00
1.2e+00
cases:3.26%
controls:1.37%
cases:2.61%
controls:0.33%
—
—
—
—
—
—
cases:3.19%
controls:0.48%
cases:6.05%
controls:1.91%
10
42
297
3024
8
10
299
3056
—
—
—
9
14
273
2923
13
44
202
2261
Other specified special examinations
Z01.8 [45581003]
8.6e-01
1.6e+00
—
—
—
2.1e+00
1.4e+00
cases:5.54%
controls:2.41%
cases:3.26%
controls:0.65%
—
—
—
—
—
—
cases:4.96%
controls:0.61%
cases:10.70%
controls:2.82%
17
74
290
2992
10
20
297
3046
—
—
—
14
18
268
2919
23
65
192
2240
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
1.2e-01
1.1e+00
2.3e+00
—
1.8e+00
7.4e-01
5.1e-01
cases:7.17%
controls:6.39%
cases:9.45%
controls:3.49%
cases:3.26%
controls:0.33%
—
—
cases:3.64%
controls:0.62%
cases:8.16%
controls:4.05%
cases:17.67%
controls:11.41%
22
196
285
2870
29
107
278
2959
10
10
297
3056
—
11
19
291
3037
23
119
259
2818
38
263
177
2042
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
1.2e+00
1.4e+00
—
—
—
2.8e+00
2.3e+00
cases:2.93%
controls:0.95%
cases:1.63%
controls:0.42%
—
—
—
—
—
—
cases:2.84%
controls:0.17%
cases:5.12%
controls:0.52%
9
29
298
3037
5
13
302
3053
—
—
—
8
5
274
2932
11
12
204
2293
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
1.5e+00
1.9e+00
—
—
—
1.8e+00
3.6e-01
cases:5.21%
controls:1.24%
cases:2.93%
controls:0.46%
—
—
—
—
—
—
cases:4.61%
controls:0.82%
cases:4.65%
controls:3.30%
16
38
291
3028
9
14
298
3052
—
—
—
13
24
269
2913
10
76
205
2229
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
7.8e-01
1.8e+00
—
—
—
2.1e+00
1.2e+00
cases:3.91%
controls:1.83%
cases:5.21%
controls:0.91%
—
—
—
—
—
—
cases:5.32%
controls:0.72%
cases:10.23%
controls:3.34%
12
56
295
3010
16
28
291
3038
—
—
—
15
21
267
2916
22
77
193
2228
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
1.1e+00
1.5e+00
2.0e+00
—
1.6e+00
1.4e+00
9.9e-01
cases:9.12%
controls:3.16%
cases:7.49%
controls:1.83%
cases:1.63%
controls:0.23%
—
—
cases:1.99%
controls:0.39%
cases:8.51%
controls:2.18%
cases:14.42%
controls:5.90%
28
97
279
2969
23
56
284
3010
5
7
302
3059
—
6
12
296
3044
24
64
258
2873
31
136
184
2169
Bacterial infection, unspecified
A49.9 [45590816]
1.0e+00
1.8e+00
—
—
—
1.8e+00
1.4e+00
cases:3.58%
controls:1.34%
cases:3.58%
controls:0.62%
—
—
—
—
—
—
cases:3.90%
controls:0.65%
cases:9.77%
controls:2.69%
11
41
296
3025
11
19
296
3047
—
—
—
11
19
271
2918
21
62
194
2243
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
1.1e+00
1.6e+00
—
—
—
1.9e+00
2.0e+00
cases:5.54%
controls:1.89%
cases:2.61%
controls:0.55%
—
—
—
—
—
—
cases:3.19%
controls:0.51%
cases:5.12%
controls:0.74%
17
58
290
3008
8
17
299
3049
—
—
—
9
15
273
2922
11
17
204
2288
FEV1
20150-9 [3024653]
1.1e+00
1.6e+00
—
—
—
1.9e+00
2.0e+00
cases:5.54%
controls:1.89%
cases:2.61%
controls:0.55%
—
—
—
—
—
—
cases:3.19%
controls:0.51%
cases:5.12%
controls:0.74%
17
58
290
3008
8
17
299
3049
—
—
—
9
15
273
2922
11
17
204
2288
FEV1/FVC
19926-5 [3011505]
1.1e+00
1.6e+00
—
—
—
1.9e+00
2.0e+00
cases:5.54%
controls:1.89%
cases:2.61%
controls:0.55%
—
—
—
—
—
—
cases:3.19%
controls:0.51%
cases:5.12%
controls:0.74%
17
58
290
3008
8
17
299
3049
—
—
—
9
15
273
2922
11
17
204
2288
Fracture of lumbar vertebra
S32.0 [45583057]
1.9e+00
—
1.0e+50
1.0e+50
—
—
3.0e+00
cases:2.61%
controls:0.39%
—
—
cases:2.28%
controls:0.00%
cases:1.63%
controls:0.00%
—
—
—
—
cases:5.12%
controls:0.26%
8
12
299
3054
—
7
0
300
3066
5
0
302
3066
—
—
11
6
204
2299
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
3.5e-01
1.3e+00
—
—
2.2e+00
1.5e+00
6.0e-01
cases:7.17%
controls:5.15%
cases:6.84%
controls:2.02%
—
—
—
—
cases:1.99%
controls:0.23%
cases:8.51%
controls:2.11%
cases:9.77%
controls:5.60%
22
158
285
2908
21
62
286
3004
—
—
6
7
296
3049
24
62
258
2875
21
129
194
2176
Oxygen saturation in Arterial blood
2708-6 [3016502]
1.2e+00
1.7e+00
—
—
—
2.0e+00
8.6e-01
cases:4.23%
controls:1.30%
cases:2.93%
controls:0.55%
—
—
—
—
—
—
cases:5.32%
controls:0.75%
cases:6.05%
controls:2.65%
13
40
294
3026
9
17
298
3049
—
—
—
15
22
267
2915
13
61
202
2244
Pelvis X-ray examination
NE1AA [2001307792]
1.2e+00
2.2e+00
—
—
—
2.7e+00
—
cases:3.58%
controls:1.11%
cases:1.95%
controls:0.23%
—
—
—
—
—
—
cases:3.90%
controls:0.27%
—
—
11
34
296
3032
6
7
301
3059
—
—
—
11
8
271
2929
—
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
1.2e+00
1.8e+00
—
—
—
1.8e+00
4.4e-01
cases:5.86%
controls:1.83%
cases:4.56%
controls:0.78%
—
—
—
—
—
—
cases:4.96%
controls:0.82%
cases:3.72%
controls:2.43%
18
56
289
3010
14
24
293
3042
—
—
—
14
24
268
2913
8
56
207
2249
Exposure to unspecified factor
X59 [45756412]
9.5e-01
1.5e+00
—
1.0e+50
—
2.7e+00
1.1e+00
cases:5.54%
controls:2.22%
cases:2.28%
controls:0.52%
—
—
cases:1.95%
controls:0.00%
—
—
cases:6.38%
controls:0.44%
cases:6.98%
controls:2.34%
17
68
290
2998
7
16
300
3050
—
6
0
301
3066
—
18
13
264
2924
15
54
200
2251
Base excess in Arterial blood by calculation
1925-7 [3003396]
1.2e+00
1.6e+00
—
—
—
2.0e+00
6.6e-01
cases:5.54%
controls:1.79%
cases:3.26%
controls:0.65%
—
—
—
—
—
—
cases:5.67%
controls:0.82%
cases:6.51%
controls:3.47%
17
55
290
3011
10
20
297
3046
—
—
—
16
24
266
2913
14
80
201
2225
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
6.6e-02
9.0e-01
2.1e+00
—
1.8e+00
6.4e-01
5.3e-01
cases:7.49%
controls:7.05%
cases:9.12%
controls:3.91%
cases:3.58%
controls:0.46%
—
—
cases:3.97%
controls:0.69%
cases:8.16%
controls:4.49%
cases:18.14%
controls:11.58%
23
216
284
2850
28
120
279
2946
11
14
296
3052
—
12
21
290
3035
23
132
259
2805
39
267
176
2038
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
2.5e-01
1.0e+00
1.5e+00
—
2.3e+00
1.4e+00
6.2e-01
cases:8.79%
controls:7.01%
cases:7.82%
controls:2.90%
cases:1.95%
controls:0.42%
—
—
cases:3.31%
controls:0.33%
cases:10.64%
controls:2.89%
cases:14.42%
controls:8.29%
27
215
280
2851
24
89
283
2977
6
13
301
3053
—
10
10
292
3046
30
85
252
2852
31
191
184
2114
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
7.6e-01
8.4e-01
1.7e+00
—
1.0e+00
8.6e-01
6.1e-01
cases:14.66%
controls:7.40%
cases:8.79%
controls:4.01%
cases:2.93%
controls:0.55%
—
—
cases:1.99%
controls:0.72%
cases:10.99%
controls:4.97%
cases:22.79%
controls:13.80%
45
227
262
2839
27
123
280
2943
9
17
298
3049
—
6
22
296
3034
31
146
251
2791
49
318
166
1987
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.0e+00
1.2e+00
—
—
—
1.5e+00
1.0e+00
cases:12.38%
controls:4.76%
cases:5.54%
controls:1.70%
—
—
—
—
—
—
cases:5.32%
controls:1.29%
cases:12.09%
controls:4.73%
38
146
269
2920
17
52
290
3014
—
—
—
15
38
267
2899
26
109
189
2196
pH of Arterial blood
2744-1 [3019977]
1.1e+00
1.6e+00
—
—
—
1.9e+00
6.7e-01
cases:5.54%
controls:1.83%
cases:3.26%
controls:0.65%
—
—
—
—
—
—
cases:5.67%
controls:0.85%
cases:6.51%
controls:3.43%
17
56
290
3010
10
20
297
3046
—
—
—
16
25
266
2912
14
79
201
2226
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
—
2.7e+00
—
—
—
2.1e+00
1.1e+00
—
—
cases:2.28%
controls:0.16%
—
—
—
—
—
—
cases:4.61%
controls:0.61%
cases:6.05%
controls:2.17%
—
7
5
300
3061
—
—
—
13
18
269
2919
13
50
202
2255
Endocrinology
46 [38004485]
1.1e+00
8.4e-01
—
—
2.0e+00
1.9e+00
1.6e+00
cases:7.49%
controls:2.51%
cases:3.26%
controls:1.44%
—
—
—
—
cases:1.66%
controls:0.23%
cases:8.87%
controls:1.43%
cases:13.02%
controls:2.82%
23
77
284
2989
10
44
297
3022
—
—
5
7
297
3049
25
42
257
2895
28
65
187
2240
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
1.1e+00
1.6e+00
—
—
—
1.9e+00
6.7e-01
cases:5.21%
controls:1.76%
cases:2.93%
controls:0.62%
—
—
—
—
—
—
cases:5.32%
controls:0.82%
cases:6.51%
controls:3.43%
16
54
291
3012
9
19
298
3047
—
—
—
15
24
267
2913
14
79
201
2226
Urinary tract infection, site not specified
N39.0 [45548665]
8.0e-01
1.8e+00
—
—
—
1.7e+00
1.2e+00
cases:5.54%
controls:2.58%
cases:4.89%
controls:0.85%
—
—
—
—
—
—
cases:4.96%
controls:0.99%
cases:12.09%
controls:4.12%
17
79
290
2987
15
26
292
3040
—
—
—
14
29
268
2908
26
95
189
2210
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
3.8e-01
7.1e-01
1.5e+00
—
1.6e+00
7.2e-01
4.0e-01
cases:34.20%
controls:26.16%
cases:19.22%
controls:10.44%
cases:5.86%
controls:1.34%
—
—
cases:7.62%
controls:1.57%
cases:17.73%
controls:9.47%
cases:29.30%
controls:21.74%
105
802
202
2264
59
320
248
2746
18
41
289
3025
—
23
48
279
3008
50
278
232
2659
63
501
152
1804
ibuprofen
R02AX02 [1588667]
3.8e-01
7.1e-01
1.5e+00
—
1.6e+00
7.2e-01
4.0e-01
cases:34.20%
controls:26.16%
cases:19.22%
controls:10.44%
cases:5.86%
controls:1.34%
—
—
cases:7.62%
controls:1.57%
cases:17.73%
controls:9.47%
cases:29.30%
controls:21.74%
105
802
202
2264
59
320
248
2746
18
41
289
3025
—
23
48
279
3008
50
278
232
2659
63
501
152
1804
salbutamol; inhalant
R03AC02 [21603256]
7.2e-01
7.4e-01
1.4e+00
—
7.4e-01
8.6e-01
8.4e-01
cases:23.45%
controls:12.98%
cases:13.03%
controls:6.69%
cases:3.58%
controls:0.88%
—
—
cases:2.65%
controls:1.28%
cases:13.83%
controls:6.33%
cases:26.51%
controls:13.45%
72
398
235
2668
40
205
267
2861
11
27
296
3039
—
8
39
294
3017
39
186
243
2751
57
310
158
1995
Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis
50797-0 [3029379]
2.0e+00
2.6e+00
—
—
—
—
1.5e+00
cases:3.91%
controls:0.55%
cases:2.93%
controls:0.23%
—
—
—
—
—
—
—
—
cases:3.72%
controls:0.82%
12
17
295
3049
9
7
298
3059
—
—
—
—
8
19
207
2286
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
1.5e+00
1.4e+00
2.3e+00
—
—
1.7e+00
1.4e+00
cases:3.26%
controls:0.78%
cases:2.93%
controls:0.72%
cases:1.63%
controls:0.16%
—
—
—
—
cases:4.96%
controls:0.99%
cases:6.98%
controls:1.78%
10
24
297
3042
9
22
298
3044
5
5
302
3061
—
—
14
29
268
2908
15
41
200
2264
Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
40976-3 [3040853]
—
2.5e+00
—
—
—
—
2.0e+00
—
—
cases:1.95%
controls:0.16%
—
—
—
—
—
—
—
—
cases:2.79%
controls:0.39%
—
6
5
301
3061
—
—
—
—
6
9
209
2296
Essential (primary) hypertension
I10 [45591453]
4.1e-01
6.6e-01
1.4e+00
—
1.3e+00
6.4e-01
5.3e-01
cases:35.83%
controls:27.10%
cases:22.48%
controls:13.08%
cases:6.51%
controls:1.73%
—
—
cases:7.62%
controls:2.29%
cases:25.53%
controls:15.25%
cases:46.98%
controls:34.32%
110
831
197
2235
69
401
238
2665
20
53
287
3013
—
23
70
279
2986
72
448
210
2489
101
791
114
1514
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
8.8e-01
1.7e+00
—
1.0e+50
—
1.8e+00
9.4e-01
cases:5.86%
controls:2.51%
cases:5.21%
controls:1.01%
—
—
cases:1.95%
controls:0.00%
—
—
cases:8.51%
controls:1.46%
cases:12.56%
controls:5.34%
18
77
289
2989
16
31
291
3035
—
6
0
301
3066
—
24
43
258
2894
27
123
188
2182
Gastroenterology
10 [38004455]
8.0e-01
1.2e+00
—
—
1.9e+00
1.2e+00
1.2e+00
cases:11.73%
controls:5.64%
cases:7.17%
controls:2.22%
—
—
—
—
cases:1.66%
controls:0.26%
cases:6.38%
controls:2.08%
cases:17.67%
controls:5.94%
36
173
271
2893
22
68
285
2998
—
—
5
8
297
3048
18
61
264
2876
38
137
177
2168
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
1.4e+00
2.3e+00
—
—
—
2.1e+00
1.1e+00
cases:2.61%
controls:0.68%
cases:2.61%
controls:0.26%
—
—
—
—
—
—
cases:3.19%
controls:0.41%
cases:2.79%
controls:0.91%
8
21
299
3045
8
8
299
3058
—
—
—
9
12
273
2925
6
21
209
2284
Dorsalgia
M54 [45553203]
8.5e-01
2.9e+00
—
—
—
—
1.5e+00
cases:2.93%
controls:1.27%
cases:4.56%
controls:0.26%
—
—
—
—
—
—
—
—
cases:5.58%
controls:1.30%
9
39
298
3027
14
8
293
3058
—
—
—
—
12
30
203
2275
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
7.7e-01
1.4e+00
—
—
—
2.1e+00
9.1e-01
cases:7.82%
controls:3.78%
cases:4.89%
controls:1.27%
—
—
—
—
—
—
cases:7.45%
controls:0.99%
cases:10.70%
controls:4.60%
24
116
283
2950
15
39
292
3027
—
—
—
21
29
261
2908
23
106
192
2199
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
5.1e-01
1.6e+00
2.7e+00
—
—
1.2e+00
6.5e-01
cases:6.84%
controls:4.21%
cases:6.84%
controls:1.47%
cases:3.91%
controls:0.26%
—
—
—
—
cases:3.90%
controls:1.23%
cases:6.05%
controls:3.25%
21
129
286
2937
21
45
286
3021
12
8
295
3058
—
—
11
36
271
2901
13
75
202
2230
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
5.1e-01
1.6e+00
2.7e+00
—
—
1.2e+00
6.5e-01
cases:6.84%
controls:4.21%
cases:6.84%
controls:1.47%
cases:3.91%
controls:0.26%
—
—
—
—
cases:3.90%
controls:1.23%
cases:6.05%
controls:3.25%
21
129
286
2937
21
45
286
3021
12
8
295
3058
—
—
11
36
271
2901
13
75
202
2230
pramipexole; oral
N04BC05 [21604477]
1.2e+00
1.3e+00
1.6e+00
—
—
1.7e+00
1.4e+00
cases:5.21%
controls:1.57%
cases:3.26%
controls:0.91%
cases:1.95%
controls:0.39%
—
—
—
—
cases:4.96%
controls:0.95%
cases:6.05%
controls:1.61%
16
48
291
3018
10
28
297
3038
6
12
301
3054
—
—
14
28
268
2909
13
37
202
2268
Pain in limb
M79.6 [45587063]
7.4e-01
1.1e+00
—
—
—
1.3e+00
1.1e+00
cases:10.75%
controls:5.45%
cases:5.86%
controls:2.02%
—
—
—
—
—
—
cases:7.09%
controls:1.97%
cases:20.00%
controls:7.98%
33
167
274
2899
18
62
289
3004
—
—
—
20
58
262
2879
43
184
172
2121
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.1e+00
1.6e+00
—
—
2.0e+00
1.5e+00
7.3e-01
cases:8.47%
controls:2.90%
cases:5.54%
controls:1.17%
—
—
—
—
cases:1.66%
controls:0.23%
cases:5.32%
controls:1.29%
cases:6.51%
controls:3.25%
26
89
281
2977
17
36
290
3030
—
—
5
7
297
3049
15
38
267
2899
14
75
201
2230
etoricoxib; oral
M01AH05 [21603996]
7.1e-01
6.8e-01
1.5e+00
—
2.0e+00
3.3e-01
4.9e-01
cases:20.85%
controls:11.45%
cases:9.12%
controls:4.86%
cases:3.26%
controls:0.75%
—
—
cases:4.30%
controls:0.62%
cases:6.03%
controls:4.39%
cases:17.67%
controls:11.67%
64
351
243
2715
28
149
279
2917
10
23
297
3043
—
13
19
289
3037
17
129
265
2808
38
269
177
2036
Parkinson disease
G20 [45538098]
1.2e+00
1.8e+00
—
—
2.3e+00
1.6e+00
7.4e-01
cases:2.28%
controls:0.72%
cases:2.61%
controls:0.42%
—
—
—
—
cases:1.66%
controls:0.16%
cases:2.13%
controls:0.44%
cases:2.79%
controls:1.34%
7
22
300
3044
8
13
299
3053
—
—
5
5
297
3051
6
13
276
2924
6
31
209
2274
oxazepam; oral
N05BA04 [21604569]
9.5e-01
1.1e+00
6.6e-01
—
8.4e-01
9.8e-01
1.1e+00
cases:12.05%
controls:5.06%
cases:8.14%
controls:2.90%
cases:1.63%
controls:0.85%
—
—
cases:1.66%
controls:0.72%
cases:8.51%
controls:3.37%
cases:16.74%
controls:6.03%
37
155
270
2911
25
89
282
2977
5
26
302
3040
—
5
22
297
3034
24
99
258
2838
36
139
179
2166
Pain general/multiple sites
A01 [2002000142]
—
—
—
—
—
2.4e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:3.19%
controls:0.31%
cases:6.98%
controls:1.26%
—
—
—
—
—
9
9
273
2928
15
29
200
2276
Back symptom/complaint
L02 [2002000627]
1.6e+00
—
—
—
—
2.5e+00
1.4e+00
cases:3.58%
controls:0.75%
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.20%
cases:4.19%
controls:1.08%
11
23
296
3043
—
—
—
—
7
6
275
2931
9
25
206
2280
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
1.1e+00
9.0e-01
—
—
—
1.8e+00
1.2e+00
cases:5.86%
controls:2.09%
cases:2.61%
controls:1.08%
—
—
—
—
—
—
cases:4.61%
controls:0.82%
cases:10.70%
controls:3.38%
18
64
289
3002
8
33
299
3033
—
—
—
13
24
269
2913
23
78
192
2227
Thrombin time
3243-3 [3036489]
8.3e-01
2.1e+00
—
—
—
2.4e+00
1.7e+00
cases:1.63%
controls:0.72%
cases:1.63%
controls:0.20%
—
—
—
—
—
—
cases:1.77%
controls:0.17%
cases:3.72%
controls:0.69%
5
22
302
3044
5
6
302
3060
—
—
—
5
5
277
2932
8
16
207
2289
Upper gastrointestinal surgery
106 [44777669]
7.2e-01
1.4e+00
1.2e+00
—
1.0e+00
1.3e+00
7.3e-01
cases:18.89%
controls:10.18%
cases:14.01%
controls:4.04%
cases:2.28%
controls:0.72%
—
—
cases:1.66%
controls:0.59%
cases:12.06%
controls:3.75%
cases:19.07%
controls:10.20%
58
312
249
2754
43
124
264
2942
7
22
300
3044
—
5
18
297
3038
34
110
248
2827
41
235
174
2070
pH of Venous blood
2746-6 [3012544]
1.2e+00
1.5e+00
—
—
—
1.4e+00
6.3e-01
cases:5.86%
controls:1.89%
cases:3.91%
controls:0.91%
—
—
—
—
—
—
cases:4.61%
controls:1.19%
cases:7.91%
controls:4.38%
18
58
289
3008
12
28
295
3038
—
—
—
13
35
269
2902
17
101
198
2204
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
1.8e+00
—
—
—
—
—
2.2e+00
cases:3.58%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
cases:5.58%
controls:0.65%
11
18
296
3048
—
—
—
—
—
12
15
203
2290
ECG with 12 standard connections
XF400 [2001303368]
1.1e+00
1.6e+00
—
—
—
1.0e+00
1.3e+00
cases:8.79%
controls:3.03%
cases:3.91%
controls:0.78%
—
—
—
—
—
—
cases:1.77%
controls:0.65%
cases:6.05%
controls:1.78%
27
93
280
2973
12
24
295
3042
—
—
—
5
19
277
2918
13
41
202
2264
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
7.2e-01
9.6e-01
2.3e+00
—
1.6e+00
5.3e-01
5.3e-01
cases:19.87%
controls:10.76%
cases:9.77%
controls:3.98%
cases:2.93%
controls:0.29%
—
—
cases:2.65%
controls:0.56%
cases:5.67%
controls:3.40%
cases:15.81%
controls:9.98%
61
330
246
2736
30
122
277
2944
9
9
298
3057
—
8
17
294
3039
16
100
266
2837
34
230
181
2075
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
1.2e+00
1.5e+00
—
—
—
1.3e+00
6.8e-01
cases:5.86%
controls:1.86%
cases:3.91%
controls:0.91%
—
—
—
—
—
—
cases:4.26%
controls:1.19%
cases:8.37%
controls:4.43%
18
57
289
3009
12
28
295
3038
—
—
—
12
35
270
2902
18
102
197
2203
Base excess in Venous blood by calculation
1927-3 [3002032]
1.2e+00
1.5e+00
—
—
—
1.3e+00
6.5e-01
cases:5.86%
controls:1.86%
cases:3.58%
controls:0.85%
—
—
—
—
—
—
cases:4.26%
controls:1.19%
cases:7.91%
controls:4.30%
18
57
289
3009
11
26
296
3040
—
—
—
12
35
270
2902
17
99
198
2206
Pain, unspecified
R52.9 [45544151]
1.3e+00
—
—
—
—
2.5e+00
1.4e+00
cases:2.28%
controls:0.62%
—
—
—
—
—
—
—
—
cases:2.84%
controls:0.24%
cases:4.65%
controls:1.21%
7
19
300
3047
—
—
—
—
8
7
274
2930
10
28
205
2277
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
3.5e-01
5.4e-01
1.4e+00
—
1.6e+00
8.9e-01
5.6e-01
cases:18.57%
controls:13.89%
cases:11.73%
controls:7.21%
cases:3.26%
controls:0.85%
—
—
cases:3.97%
controls:0.82%
cases:14.89%
controls:6.67%
cases:24.19%
controls:15.44%
57
426
250
2640
36
221
271
2845
10
26
297
3040
—
12
25
290
3031
42
196
240
2741
52
356
163
1949
Dorsalgia, unspecified
M54.9 [45538791]
1.9e+00
—
1.0e+50
1.0e+50
—
—
1.9e+00
cases:3.26%
controls:0.52%
—
—
cases:3.58%
controls:0.00%
cases:2.28%
controls:0.00%
—
—
—
—
cases:6.05%
controls:0.91%
10
16
297
3050
—
11
0
296
3066
7
0
300
3066
—
—
13
21
202
2284
Bacteria identified in Isolate by Culture
43409-2 [3042936]
1.2e+00
1.2e+00
—
—
—
1.4e+00
1.2e+00
cases:6.51%
controls:2.05%
cases:3.26%
controls:1.04%
—
—
—
—
—
—
cases:3.90%
controls:1.02%
cases:10.23%
controls:3.30%
20
63
287
3003
10
32
297
3034
—
—
—
11
30
271
2907
22
76
193
2229
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
4.0e-01
1.0e+00
1.8e+00
—
1.2e+00
9.5e-01
5.7e-01
cases:13.68%
controls:9.62%
cases:11.40%
controls:4.53%
cases:4.89%
controls:0.82%
—
—
cases:1.99%
controls:0.62%
cases:12.77%
controls:5.38%
cases:23.26%
controls:14.58%
42
295
265
2771
35
139
272
2927
15
25
292
3041
—
6
19
296
3037
36
158
246
2779
50
336
165
1969
magnesium hydroxide; oral
G04BX01 [21602658]
1.4e+00
2.0e+00
—
—
—
1.7e+00
1.3e+00
cases:1.63%
controls:0.39%
cases:2.61%
controls:0.36%
—
—
—
—
—
—
cases:2.84%
controls:0.51%
cases:3.72%
controls:1.04%
5
12
302
3054
8
11
299
3055
—
—
—
8
15
274
2922
8
24
207
2281
magnesium hydroxide; oral
A02AA04 [21600052]
1.4e+00
2.0e+00
—
—
—
1.7e+00
1.3e+00
cases:1.63%
controls:0.39%
cases:2.61%
controls:0.36%
—
—
—
—
—
—
cases:2.84%
controls:0.51%
cases:3.72%
controls:1.04%
5
12
302
3054
8
11
299
3055
—
—
—
8
15
274
2922
8
24
207
2281
lansoprazole; oral
A02BC03 [21600098]
8.2e-01
1.1e+00
1.8e+00
—
1.1e+00
7.2e-01
5.9e-01
cases:10.42%
controls:4.89%
cases:6.51%
controls:2.28%
cases:2.93%
controls:0.49%
—
—
cases:1.66%
controls:0.56%
cases:4.96%
controls:2.49%
cases:7.44%
controls:4.25%
32
150
275
2916
20
70
287
2996
9
15
298
3051
—
5
17
297
3039
14
73
268
2864
16
98
199
2207
Retention of urine
R33 [45587507]
3.3e-01
—
—
—
—
1.9e+00
1.7e+00
cases:1.63%
controls:1.17%
—
—
—
—
—
—
—
—
cases:3.19%
controls:0.48%
cases:4.19%
controls:0.78%
5
36
302
3030
—
—
—
—
9
14
273
2923
9
18
206
2287
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
3.5e-01
1.1e+00
1.8e+00
—
1.3e+00
8.8e-01
8.0e-01
cases:7.49%
controls:5.41%
cases:5.54%
controls:1.99%
cases:2.28%
controls:0.39%
—
—
cases:1.99%
controls:0.56%
cases:5.32%
controls:2.28%
cases:13.95%
controls:6.81%
23
166
284
2900
17
61
290
3005
7
12
300
3054
—
6
17
296
3039
15
67
267
2870
30
157
185
2148
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
3.6e-01
1.4e+00
2.2e+00
—
1.5e+00
9.0e-01
6.5e-01
cases:5.54%
controls:3.95%
cases:7.49%
controls:1.96%
cases:3.26%
controls:0.36%
—
—
cases:2.65%
controls:0.59%
cases:6.03%
controls:2.55%
cases:9.77%
controls:5.34%
17
121
290
2945
23
60
284
3006
10
11
297
3055
—
8
18
294
3038
17
75
265
2862
21
123
194
2182
Polymyalgia rheumatica
M35.3 [45533830]
1.7e+00
1.9e+00
—
—
—
1.6e+00
1.4e+00
cases:2.93%
controls:0.55%
cases:2.61%
controls:0.39%
—
—
—
—
—
—
cases:2.13%
controls:0.44%
cases:3.72%
controls:0.95%
9
17
298
3049
8
12
299
3054
—
—
—
6
13
276
2924
8
22
207
2283
nystatin
D01AA01 [21601911]
1.5e+00
—
—
—
—
—
2.0e+00
cases:2.93%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:3.72%
controls:0.52%
9
20
298
3046
—
—
—
—
—
8
12
207
2293
metronidazole and furazolidone
P01AB51 [45893518]
1.5e+00
—
—
—
—
—
2.0e+00
cases:2.93%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:3.72%
controls:0.52%
9
20
298
3046
—
—
—
—
—
8
12
207
2293
nystatin; vaginal
G01AA01 [21602363]
1.5e+00
—
—
—
—
—
2.0e+00
cases:2.93%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:3.72%
controls:0.52%
9
20
298
3046
—
—
—
—
—
8
12
207
2293
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
8.3e-01
1.0e+00
2.2e+00
1.0e+50
—
1.4e+00
9.6e-01
cases:5.86%
controls:2.64%
cases:3.26%
controls:1.17%
cases:1.95%
controls:0.23%
cases:2.28%
controls:0.00%
—
—
cases:4.96%
controls:1.33%
cases:7.44%
controls:2.99%
18
81
289
2985
10
36
297
3030
6
7
301
3059
7
0
300
3066
—
14
39
268
2898
16
69
199
2236
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
9.8e-01
1.6e+00
—
—
—
1.9e+00
6.7e-01
cases:4.56%
controls:1.76%
cases:2.93%
controls:0.62%
—
—
—
—
—
—
cases:5.32%
controls:0.82%
cases:6.51%
controls:3.43%
14
54
293
3012
9
19
298
3047
—
—
—
15
24
267
2913
14
79
201
2226
triamcinolone and antiinfectives
S02CA04 [21605176]
1.5e+00
—
—
—
—
—
1.9e+00
cases:2.93%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:3.72%
controls:0.56%
9
20
298
3046
—
—
—
—
—
8
13
207
2292
Dentistry
C5 [903277]
1.3e+00
1.0e+00
—
—
—
2.1e+00
9.0e-01
cases:4.89%
controls:1.34%
cases:1.63%
controls:0.59%
—
—
—
—
—
—
cases:3.19%
controls:0.41%
cases:4.65%
controls:1.95%
15
41
292
3025
5
18
302
3048
—
—
—
9
12
273
2925
10
45
205
2260
Dry eye syndrome
H04.10 [2000502254]
1.3e+00
1.3e+00
—
—
—
2.1e+00
7.1e-01
cases:3.58%
controls:1.01%
cases:2.28%
controls:0.62%
—
—
—
—
—
—
cases:2.48%
controls:0.31%
cases:2.79%
controls:1.39%
11
31
296
3035
7
19
300
3047
—
—
—
7
9
275
2928
6
32
209
2273
Acute cystitis
N30.0 [45601724]
5.7e-01
1.1e+00
2.5e+00
—
—
9.7e-01
8.9e-01
cases:4.23%
controls:2.45%
cases:3.26%
controls:1.14%
cases:1.95%
controls:0.16%
—
—
—
—
cases:2.84%
controls:1.09%
cases:10.70%
controls:4.69%
13
75
294
2991
10
35
297
3031
6
5
301
3061
—
—
8
32
274
2905
23
108
192
2197
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
1.1e+00
1.5e+00
—
—
—
1.9e+00
9.2e-01
cases:2.61%
controls:0.91%
cases:2.93%
controls:0.68%
—
—
—
—
—
—
cases:3.55%
controls:0.54%
cases:6.51%
controls:2.69%
8
28
299
3038
9
21
298
3045
—
—
—
10
16
272
2921
14
62
201
2243
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
1.4e+00
1.9e+00
—
—
—
1.4e+00
1.3e+00
cases:4.56%
controls:1.17%
cases:5.21%
controls:0.78%
—
—
—
—
—
—
cases:2.84%
controls:0.68%
cases:5.12%
controls:1.52%
14
36
293
3030
16
24
291
3042
—
—
—
8
20
274
2917
11
35
204
2270
furosemide; oral, parenteral
C03CA01 [21601518]
5.4e-01
7.6e-01
6.0e-01
—
7.2e-01
8.5e-01
1.1e+00
cases:18.57%
controls:11.71%
cases:19.87%
controls:10.37%
cases:6.51%
controls:3.69%
—
—
cases:7.28%
controls:3.70%
cases:21.99%
controls:10.73%
cases:37.21%
controls:16.23%
57
359
250
2707
61
318
246
2748
20
113
287
2953
—
22
113
280
2943
62
315
220
2622
80
374
135
1931
Home Visit
OMOP4822459 [581476]
2.2e-01
5.2e-01
8.1e-01
5.2e-01
1.3e+00
1.4e+00
5.8e-01
cases:11.40%
controls:9.33%
cases:10.75%
controls:6.69%
cases:5.86%
controls:2.71%
cases:2.28%
controls:1.37%
cases:10.26%
controls:3.08%
cases:23.40%
controls:7.18%
cases:30.23%
controls:19.48%
35
286
272
2780
33
205
274
2861
18
83
289
2983
7
42
300
3024
31
94
271
2962
66
211
216
2726
65
449
150
1856
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
2.3e-01
5.3e-01
—
—
2.5e+00
7.6e-01
5.6e-01
cases:10.42%
controls:8.48%
cases:6.84%
controls:4.14%
—
—
—
—
cases:2.98%
controls:0.26%
cases:9.57%
controls:4.73%
cases:19.07%
controls:11.84%
32
260
275
2806
21
127
286
2939
—
—
9
8
293
3048
27
139
255
2798
41
273
174
2032
dexamethasone; oral, parenteral
H02AB02 [21602730]
8.5e-01
1.4e+00
—
—
—
1.8e+00
9.4e-01
cases:5.54%
controls:2.45%
cases:4.23%
controls:1.08%
—
—
—
—
—
—
cases:4.96%
controls:0.85%
cases:7.44%
controls:3.04%
17
75
290
2991
13
33
294
3033
—
—
—
14
25
268
2912
16
70
199
2235
potassium chloride; oral
A12BA01 [21600877]
1.0e+00
2.0e-01
9.7e-01
—
6.0e-01
1.2e+00
1.0e+00
cases:8.47%
controls:3.29%
cases:2.93%
controls:2.41%
cases:2.28%
controls:0.88%
—
—
cases:1.66%
controls:0.92%
cases:6.03%
controls:1.97%
cases:12.56%
controls:4.95%
26
101
281
2965
9
74
298
2992
7
27
300
3039
—
5
28
297
3028
17
58
265
2879
27
114
188
2191
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
1.0e+00
1.4e+00
—
—
—
2.1e+00
1.0e+00
cases:5.54%
controls:2.05%
cases:2.93%
controls:0.75%
—
—
—
—
—
—
cases:4.96%
controls:0.61%
cases:6.05%
controls:2.30%
17
63
290
3003
9
23
298
3043
—
—
—
14
18
268
2919
13
53
202
2252
Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]
3.1e+00
—
—
1.0e+50
—
—
—
cases:3.58%
controls:0.16%
—
—
—
—
cases:1.95%
controls:0.00%
—
—
—
—
—
—
11
5
296
3061
—
—
6
0
301
3066
—
—
—
cefalexin; oral
J01DB01 [21602870]
7.8e-01
7.1e-01
9.9e-01
—
—
8.0e-01
8.3e-01
cases:43.00%
controls:25.77%
cases:15.96%
controls:8.51%
cases:2.93%
controls:1.11%
—
—
—
—
cases:16.31%
controls:8.04%
cases:42.79%
controls:24.69%
132
790
175
2276
49
261
258
2805
9
34
298
3032
—
—
46
236
236
2701
92
569
123
1736
Malaise and fatigue
R53 [45553741]
9.8e-01
1.3e+00
—
—
—
6.4e-01
8.3e-01
cases:8.14%
controls:3.23%
cases:4.89%
controls:1.40%
—
—
—
—
—
—
cases:3.55%
controls:1.91%
cases:13.95%
controls:6.59%
25
99
282
2967
15
43
292
3023
—
—
—
10
56
272
2881
30
152
185
2153
warfarin; oral, parenteral
B01AA03 [21600965]
6.7e-01
7.8e-01
3.5e-01
—
9.7e-01
6.9e-01
9.2e-01
cases:16.61%
controls:9.23%
cases:14.98%
controls:7.50%
cases:2.93%
controls:2.09%
—
—
cases:3.31%
controls:1.28%
cases:13.48%
controls:7.22%
cases:18.60%
controls:8.33%
51
283
256
2783
46
230
261
2836
9
64
298
3002
—
10
39
292
3017
38
212
244
2725
40
192
175
2113
omeprazole; oral, parenteral
A02BC01 [21600096]
8.8e-01
1.1e+00
—
—
—
1.0e+00
6.2e-01
cases:9.45%
controls:4.14%
cases:5.21%
controls:1.79%
—
—
—
—
—
—
cases:5.32%
controls:1.97%
cases:7.44%
controls:4.16%
29
127
278
2939
16
55
291
3011
—
—
—
15
58
267
2879
16
96
199
2209
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
8.1e-01
7.5e-01
—
—
—
2.1e+00
9.3e-01
cases:6.51%
controls:3.00%
cases:2.93%
controls:1.40%
—
—
—
—
—
—
cases:6.03%
controls:0.82%
cases:10.23%
controls:4.30%
20
92
287
2974
9
43
298
3023
—
—
—
17
24
265
2913
22
99
193
2206
Ultrasound examination of lower leg veins
PH2AE [2001309451]
1.4e+00
1.8e+00
—
—
—
1.6e+00
1.2e+00
cases:3.58%
controls:0.95%
cases:1.63%
controls:0.26%
—
—
—
—
—
—
cases:2.84%
controls:0.58%
cases:5.58%
controls:1.78%
11
29
296
3037
5
8
302
3058
—
—
—
8
17
274
2920
12
41
203
2264
Other seropositive rheumatoid arthritis
M05.8 [45538634]
1.5e+00
1.5e+00
—
1.0e+50
1.5e+00
1.1e+00
8.4e-01
cases:5.86%
controls:1.40%
cases:3.91%
controls:0.91%
—
—
cases:1.63%
controls:0.00%
cases:1.66%
controls:0.36%
cases:2.84%
controls:0.92%
cases:3.26%
controls:1.43%
18
43
289
3023
12
28
295
3038
—
5
0
302
3066
5
11
297
3045
8
27
274
2910
7
33
208
2272
temazepam; oral
N05CD07 [21604642]
8.0e-01
1.0e+00
—
—
—
8.6e-01
1.1e+00
cases:9.77%
controls:4.63%
cases:7.17%
controls:2.71%
—
—
—
—
—
—
cases:6.38%
controls:2.79%
cases:12.09%
controls:4.38%
30
142
277
2924
22
83
285
2983
—
—
—
18
82
264
2855
26
101
189
2204
Other specified urinary incontinence
N39.4 [45577525]
5.4e-01
1.7e+00
—
—
—
1.2e+00
1.2e+00
cases:2.93%
controls:1.73%
cases:3.91%
controls:0.75%
—
—
—
—
—
—
cases:2.48%
controls:0.78%
cases:7.91%
controls:2.43%
9
53
298
3013
12
23
295
3043
—
—
—
7
23
275
2914
17
56
198
2249
Issue of repeat prescription
Z76.0 [45542456]
1.3e+00
9.6e-01
-1.0e+50
—
—
1.6e+00
7.1e-01
cases:6.19%
controls:1.70%
cases:2.93%
controls:1.14%
cases:0.00%
controls:0.16%
—
—
—
—
cases:5.67%
controls:1.23%
cases:8.84%
controls:4.56%
19
52
288
3014
9
35
298
3031
0
5
307
3061
—
—
16
36
266
2901
19
105
196
2200
Specific gravity of Urine by Refractometry
5810-7 [3019150]
5.1e-01
1.0e+00
1.7e+00
—
1.9e+00
8.3e-01
5.7e-01
cases:8.47%
controls:5.28%
cases:8.14%
controls:3.10%
cases:2.28%
controls:0.42%
—
—
cases:2.98%
controls:0.46%
cases:7.09%
controls:3.23%
cases:16.28%
controls:9.89%
26
162
281
2904
25
95
282
2971
7
13
300
3053
—
9
14
293
3042
20
95
262
2842
35
228
180
2077
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
1.1e+00
1.8e+00
—
—
—
—
1.1e+00
cases:5.54%
controls:1.89%
cases:4.56%
controls:0.78%
—
—
—
—
—
—
—
—
cases:5.58%
controls:1.95%
17
58
290
3008
14
24
293
3042
—
—
—
—
12
45
203
2260
zopiclone; oral
N05CF01 [21604654]
5.9e-01
7.1e-01
6.9e-01
—
8.8e-01
8.3e-01
7.8e-01
cases:18.24%
controls:10.96%
cases:13.03%
controls:6.88%
cases:3.58%
controls:1.83%
—
—
cases:4.30%
controls:1.83%
cases:14.89%
controls:7.08%
cases:20.47%
controls:10.59%
56
336
251
2730
40
211
267
2855
11
56
296
3010
—
13
56
289
3000
42
208
240
2729
44
244
171
2061
pivmecillinam; oral
J01CA08 [21602827]
5.3e-01
5.1e-01
1.7e+00
—
—
5.0e-01
6.9e-01
cases:19.54%
controls:12.52%
cases:8.79%
controls:5.48%
cases:3.58%
controls:0.68%
—
—
—
—
cases:8.51%
controls:5.35%
cases:24.65%
controls:14.14%
60
384
247
2682
27
168
280
2898
11
21
296
3045
—
—
24
157
258
2780
53
326
162
1979
venlafaxine; oral
N06AX16 [21604745]
1.3e+00
1.0e+00
—
—
—
1.0e+00
1.6e+00
cases:3.91%
controls:1.11%
cases:2.28%
controls:0.82%
—
—
—
—
—
—
cases:2.84%
controls:1.02%
cases:6.98%
controls:1.48%
12
34
295
3032
7
25
300
3041
—
—
—
8
30
274
2907
15
34
200
2271
Tissue transglutaminase IgG Ab [Units/volume] in Serum
32998-7 [3046870]
1.2e+00
—
—
—
—
2.9e+00
1.2e+00
cases:1.95%
controls:0.59%
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.20%
cases:3.72%
controls:1.17%
6
18
301
3048
—
—
—
—
10
6
272
2931
8
27
207
2278
Cathetrisation of vein
TPH04 [2001309597]
1.2e+00
1.2e+00
—
—
—
1.6e+00
7.8e-01
cases:9.45%
controls:2.90%
cases:3.26%
controls:1.01%
—
—
—
—
—
—
cases:6.38%
controls:1.33%
cases:8.37%
controls:4.03%
29
89
278
2977
10
31
297
3035
—
—
—
18
39
264
2898
18
93
197
2212
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
1.3e+00
1.4e+00
—
—
-1.0e+50
1.5e+00
7.9e-01
cases:4.89%
controls:1.34%
cases:2.28%
controls:0.55%
—
—
—
—
cases:0.00%
controls:0.16%
cases:3.55%
controls:0.78%
cases:4.19%
controls:1.95%
15
41
292
3025
7
17
300
3049
—
—
0
5
302
3051
10
23
272
2914
9
45
206
2260
FEV1/FVC --post bronchodilation
69970-2 [42868459]
1.1e+00
1.4e+00
—
—
—
1.4e+00
1.8e+00
cases:4.89%
controls:1.70%
cases:1.95%
controls:0.49%
—
—
—
—
—
—
cases:2.13%
controls:0.51%
cases:4.19%
controls:0.74%
15
52
292
3014
6
15
301
3051
—
—
—
6
15
276
2922
9
17
206
2288
FVC percent change Respiratory system
69982-7 [42868471]
1.1e+00
1.4e+00
—
—
—
1.4e+00
1.8e+00
cases:4.89%
controls:1.70%
cases:1.95%
controls:0.49%
—
—
—
—
—
—
cases:2.13%
controls:0.51%
cases:4.19%
controls:0.74%
15
52
292
3014
6
15
301
3051
—
—
—
6
15
276
2922
9
17
206
2288
FEV1 --post bronchodilation
20155-8 [3023550]
1.1e+00
1.4e+00
—
—
—
1.4e+00
1.8e+00
cases:4.89%
controls:1.70%
cases:1.95%
controls:0.49%
—
—
—
—
—
—
cases:2.13%
controls:0.51%
cases:4.19%
controls:0.74%
15
52
292
3014
6
15
301
3051
—
—
—
6
15
276
2922
9
17
206
2288
FEV1 percent change
69983-5 [42868472]
1.1e+00
1.4e+00
—
—
—
1.4e+00
1.8e+00
cases:4.89%
controls:1.70%
cases:1.95%
controls:0.49%
—
—
—
—
—
—
cases:2.13%
controls:0.51%
cases:4.19%
controls:0.74%
15
52
292
3014
6
15
301
3051
—
—
—
6
15
276
2922
9
17
206
2288
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
1.1e+00
1.4e+00
—
—
—
1.4e+00
1.8e+00
cases:4.89%
controls:1.70%
cases:1.95%
controls:0.49%
—
—
—
—
—
—
cases:2.13%
controls:0.51%
cases:4.19%
controls:0.74%
15
52
292
3014
6
15
301
3051
—
—
—
6
15
276
2922
9
17
206
2288
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
—
2.3e+00
—
—
—
2.8e+00
—
—
—
cases:1.63%
controls:0.16%
—
—
—
—
—
—
cases:2.84%
controls:0.17%
—
—
—
5
5
302
3061
—
—
—
8
5
274
2932
—
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
7.4e-01
1.2e+00
—
—
—
1.7e+00
7.3e-01
cases:7.17%
controls:3.56%
cases:4.56%
controls:1.47%
—
—
—
—
—
—
cases:7.09%
controls:1.43%
cases:11.16%
controls:5.68%
22
109
285
2957
14
45
293
3021
—
—
—
20
42
262
2895
24
131
191
2174
ferrous glycine sulfate; oral
B03AA01 [21601080]
1.0e+00
9.7e-01
—
—
—
1.7e+00
1.1e+00
cases:3.58%
controls:1.30%
cases:2.28%
controls:0.88%
—
—
—
—
—
—
cases:3.55%
controls:0.68%
cases:6.51%
controls:2.21%
11
40
296
3026
7
27
300
3039
—
—
—
10
20
272
2917
14
51
201
2254
Coloscopy
UJF32 [2001305029]
5.8e-01
9.3e-01
—
—
—
1.6e+00
1.2e+00
cases:9.12%
controls:5.32%
cases:3.26%
controls:1.30%
—
—
—
—
—
—
cases:5.32%
controls:1.16%
cases:12.09%
controls:3.86%
28
163
279
2903
10
40
297
3026
—
—
—
15
34
267
2903
26
89
189
2216
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
1.4e+00
1.4e+00
—
—
—
1.9e+00
1.4e+00
cases:3.91%
controls:0.98%
cases:2.28%
controls:0.59%
—
—
—
—
—
—
cases:1.77%
controls:0.27%
cases:5.58%
controls:1.48%
12
30
295
3036
7
18
300
3048
—
—
—
5
8
277
2929
12
34
203
2271
Supine thorax X-ray examination
GD1QA [2001303648]
7.4e-01
1.1e+00
—
—
—
1.7e+00
1.0e+00
cases:6.51%
controls:3.23%
cases:3.26%
controls:1.14%
—
—
—
—
—
—
cases:8.87%
controls:1.67%
cases:13.95%
controls:5.55%
20
99
287
2967
10
35
297
3031
—
—
—
25
49
257
2888
30
128
185
2177
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
5.0e-01
6.9e-01
1.4e+00
—
2.1e+00
6.9e-01
5.1e-01
cases:17.92%
controls:11.74%
cases:10.10%
controls:5.32%
cases:1.95%
controls:0.49%
—
—
cases:3.97%
controls:0.52%
cases:10.99%
controls:5.86%
cases:28.37%
controls:19.26%
55
360
252
2706
31
163
276
2903
6
15
301
3051
—
12
16
290
3040
31
172
251
2765
61
444
154
1861
Fracture of thoracic vertebra
S22.0 [45592654]
2.7e+00
—
1.0e+50
1.0e+50
—
—
—
cases:2.93%
controls:0.20%
—
—
cases:2.28%
controls:0.00%
cases:2.61%
controls:0.00%
—
—
—
—
—
—
9
6
298
3060
—
7
0
300
3066
8
0
299
3066
—
—
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
1.1e+00
7.7e-01
1.9e+00
—
1.9e+00
9.8e-01
6.5e-01
cases:10.10%
controls:3.65%
cases:6.19%
controls:2.97%
cases:1.95%
controls:0.29%
—
—
cases:1.66%
controls:0.26%
cases:7.80%
controls:3.06%
cases:20.47%
controls:11.80%
31
112
276
2954
19
91
288
2975
6
9
301
3057
—
5
8
297
3048
22
90
260
2847
44
272
171
2033
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.1e+00
1.6e+00
—
—
—
1.6e+00
9.4e-01
cases:7.17%
controls:2.45%
cases:3.26%
controls:0.68%
—
—
—
—
—
—
cases:2.84%
controls:0.61%
cases:6.51%
controls:2.65%
22
75
285
2991
10
21
297
3045
—
—
—
8
18
274
2919
14
61
201
2244
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
1.2e+00
1.5e+00
—
—
—
1.1e+00
7.5e-01
cases:4.56%
controls:1.37%
cases:3.26%
controls:0.78%
—
—
—
—
—
—
cases:3.19%
controls:1.06%
cases:7.91%
controls:3.90%
14
42
293
3024
10
24
297
3042
—
—
—
9
31
273
2906
17
90
198
2215
Atherosclerotic heart disease
I25.1 [45596196]
5.6e-01
1.0e+00
1.4e+00
—
1.1e+00
8.1e-01
8.1e-01
cases:10.75%
controls:6.43%
cases:9.12%
controls:3.52%
cases:2.28%
controls:0.59%
—
—
cases:2.65%
controls:0.88%
cases:8.16%
controls:3.81%
cases:16.74%
controls:8.20%
33
197
274
2869
28
108
279
2958
7
18
300
3048
—
8
27
294
3029
23
112
259
2825
36
189
179
2116
ispaghula (psylla seeds); oral
A06AC01 [21600555]
3.6e-01
8.2e-01
7.8e-01
—
1.2e+00
1.0e+00
8.1e-01
cases:7.82%
controls:5.58%
cases:7.17%
controls:3.29%
cases:1.63%
controls:0.75%
—
—
cases:1.66%
controls:0.52%
cases:7.80%
controls:3.03%
cases:14.88%
controls:7.20%
24
171
283
2895
22
101
285
2965
5
23
302
3043
—
5
16
297
3040
22
89
260
2848
32
166
183
2139

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
153
723
3.22
22.58
5.4
3.3
0.40
0.51
e6/l
0.39
117
553
45
94
5.44
21.10
14.9
3.6
68.25
72.91
mg/l
0.05
38
77
45
94
5.44
21.10
15.1
3.7
53.44
62.78
mg/l
0.09
38
77
43
88
5.52
20.60
14.2
3.3
52.06
4.32
ratio
0.47
26
51
157
787
3.03
20.35
7.6
4.0
—
—
—
0
0
165
863
2.96
19.59
5.8
3.3
29.64
126.06
e6/l
0.72
126
678
204
1200
3.07
19.46
9.4
4.5
33.76
34.60
g/l
1.28
184
1101
68
210
3.87
19.43
10.0
2.4
—
—
—
0
0
177
971
2.93
19.08
7.4
3.9
139.96
142.08
e6/l
0.01
130
708
100
402
3.20
18.89
5.5
3.0
4.10
3.06
e6/l
0.27
49
212
158
824
2.88
18.60
10.5
5.5
—
—
—
0
0
144
716
2.90
18.53
3.0
2.3
2.95
3.09
mg/l
0.27
118
597
100
419
3.05
17.41
3.9
2.3
20.66
21.39
%
0.22
93
381
108
477
2.95
17.06
4.0
2.3
11.51
11.90
umol/l
0.21
101
432
100
424
3.01
16.99
4.8
2.9
0.92
1.48
e6/l
0.99
50
232
191
1139
2.78
16.78
3.5
2.3
82.35
79.36
nmol/l
0.72
176
977
158
857
2.73
16.76
10.0
3.8
7.40
7.40
ph
0.29
125
609
219
1404
2.94
16.68
16.1
6.6
1.20
1.21
mmol/l
1.24
189
1175
103
449
2.94
16.60
3.9
2.3
2.20
2.26
g/l
0.43
97
404
33
65
5.57
16.39
3.2
1.6
—
—
—
0
0
89
363
3.04
16.10
3.0
2.7
1.79
1.81
%
0.07
79
320
209
1326
2.79
15.90
10.6
6.6
10.89
12.47
umol/l
1.54
195
1255
166
942
2.65
15.80
4.6
3.4
2.33
2.36
mmol/l
2.62
156
838
95
407
2.93
15.69
2.8
1.8
3.08
2.57
g/l
0.35
58
228
177
1051
2.61
15.13
5.1
3.8
6.62
6.28
ph
2.70
94
576
74
283
3.13
14.87
2.9
2.9
65.19
69.53
e9/l
0.47
43
209
55
178
3.54
14.44
6.3
3.3
10.88
10.83
g/l
0.02
48
161
205
1331
2.62
14.16
6.7
4.3
29.85
0.00
estimate
0.49
46
314
195
1241
2.56
13.98
16.4
6.0
1.20
1.21
mmol/l
2.57
184
1111
112
552
2.62
13.86
4.5
3.1
503.55
525.75
mosm/kgh2o
0.58
98
485
74
296
2.97
13.66
2.0
1.8
—
—
—
0
0
63
230
3.19
13.61
13.7
7.4
—
—
—
0
0
127
670
2.52
13.58
5.2
3.6
0.00
0.00
—
5
34
202
1320
2.54
13.48
6.6
4.3
0.00
0.00
estimate
-0.00
42
298
98
462
2.64
13.18
1.4
1.3
2.04
0.95
u/ml
0.69
22
110
136
752
2.45
13.01
3.5
2.4
50.64
66.15
u/l
1.67
123
687
171
1048
2.42
12.97
4.8
2.8
137.46
138.87
ug/l
0.03
156
942
164
987
2.42
12.96
4.7
3.4
2158.12
1877.11
ng/l
0.23
142
850
163
979
2.41
12.93
5.3
3.4
—
—
—
0
0
192
1243
2.45
12.81
12.2
5.7
1.58
1.77
e9/l
2.14
160
1091
202
1343
2.46
12.62
29.7
17.5
1.40
1.35
inr
0.48
177
1122
193
1258
2.43
12.60
12.1
5.7
0.19
0.19
e9/l
0.02
160
1084
201
1341
2.44
12.34
6.8
4.3
0.00
0.00
estimate
0.50
44
293
179
1136
2.37
12.32
12.4
6.0
9.90
9.11
%
2.15
166
1058
68
274
2.90
12.29
4.7
2.0
7.25
10.11
umol/l
0.98
56
239
181
1155
2.38
12.29
12.6
6.0
23.19
25.92
%
2.83
169
1093
179
1137
2.37
12.28
12.4
5.8
2.95
2.75
%
0.50
165
1060
179
1138
2.37
12.24
12.4
5.9
0.74
0.65
%
1.34
166
1057
188
1221
2.39
12.23
12.0
5.6
0.64
0.60
e9/l
1.21
150
1039
188
1227
2.37
12.01
12.0
5.6
0.04
0.04
e9/l
0.81
150
1051
46
149
3.45
11.99
4.0
2.0
0.91
1.82
g/l
1.19
41
134
203
1371
2.41
11.96
18.7
9.3
4.46
4.25
e9/l
0.53
174
1200
21
36
6.19
11.96
3.7
2.3
0.26
1.07
g/24h
1.94
16
21
251
1882
2.80
11.60
16.9
7.8
83.94
81.22
u/l
0.36
239
1741
59
228
2.96
11.45
4.4
3.2
77.77
82.19
ng/l
0.19
49
190
177
1141
2.30
11.43
12.6
5.9
60.66
58.81
%
1.26
169
1089
58
223
2.97
11.36
2.6
2.0
33.00
34.41
u/l
0.10
47
188
76
341
2.63
11.10
11.0
6.6
1.53
1.31
mmol/l
0.14
68
284
76
341
2.63
11.10
11.2
6.6
7.41
7.42
ph
0.40
35
212
67
283
2.75
11.01
6.2
3.1
3.17
2.18
mmol/l
1.40
62
240
68
296
2.66
10.50
6.2
3.1
7.38
7.38
ph
0.01
38
194
169
1098
2.19
10.34
3.9
2.7
—
—
estimate
—
0
0
111
614
2.26
10.09
3.7
2.7
5.18
6.02
e6/l
0.44
105
566
79
378
2.47
9.99
2.4
2.0
—
—
—
0
0
182
1231
2.17
9.89
2.8
2.2
92.82
95.85
pmol/l
0.32
99
606
140
857
2.16
9.83
2.2
1.7
18.91
20.01
nmol/l
0.40
119
689
104
571
2.24
9.54
4.4
3.0
2.47
2.47
mmol/l
0.09
96
515
22
32
7.32
9.50
4.8
2.6
—
—
—
0
0
15
13
12.06
8.66
2.5
1.7
—
—
—
0
0
131
815
2.06
8.51
3.0
2.0
237.10
292.98
u/l
0.17
120
767
131
818
2.05
8.40
4.2
2.4
—
—
—
0
0
160
1074
2.02
8.38
6.8
4.1
46.15
71.84
ng/l
0.38
132
840
53
227
2.61
8.36
2.5
2.1
344.57
421.76
nmol/l
1.19
47
205
36
131
2.98
7.69
2.0
1.8
0.28
3.82
ug/l
0.98
28
115
40
156
2.80
7.54
1.1
1.2
—
—
—
0
0
191
1401
1.96
7.37
4.8
3.0
68.86
52.89
u/l
1.26
175
1275
97
569
2.03
7.19
2.2
1.8
1112.38
1080.74
nmol/l
0.12
72
416
18
43
4.38
7.11
1.9
1.9
7.97
8.14
pmol/l
0.03
18
43
202
1537
1.91
6.68
12.0
4.8
6.87
6.80
mmol/l
0.16
194
1454
61
310
2.21
6.52
1.4
1.2
—
—
—
0
0
154
1082
1.85
6.48
24.4
11.5
0.00
0.00
e9/l
0.30
116
903
34
132
2.77
6.46
1.6
1.4
—
—
—
0
0
58
290
2.23
6.45
1.5
1.3
640.00
436.00
titre
—
10
70
63
332
2.13
6.13
1.4
1.2
41.40
15.75
u/ml
0.62
19
114
22
69
3.36
6.00
5.5
4.0
0.81
1.68
index
0.61
16
38
27
97
2.95
5.90
4.2
3.6
0.72
0.77
nmol/l
0.18
22
79
90
549
1.90
5.80
6.3
3.8
89.82
360.23
ng/l
2.22
79
471
56
288
2.15
5.79
1.7
1.4
—
—
—
0
0
68
377
2.03
5.77
1.5
1.2
32.01
35.77
iu/ml
0.12
25
126
15
27
5.78
5.76
1.3
1.4
—
—
—
0
0
83
506
1.88
5.30
3.3
1.7
1.65
1.44
mg/l
0.22
73
408
13
22
6.12
5.28
2.5
3.3
577.23
885.32
mg
0.34
13
22
49
249
2.15
5.20
2.3
2.4
5.65
6.53
ug/l
0.21
39
215
267
2311
2.17
5.17
45.9
17.4
27.22
25.74
mg/l
0.37
252
1972
16
45
3.70
5.11
3.1
2.0
2.74
2.30
mmol/l
0.16
11
29
46
232
2.16
4.97
1.7
1.5
—
—
—
0
0
42
205
2.21
4.92
6.1
4.3
0.00
0.15
%
1.42
13
61
95
621
1.77
4.78
4.5
3.0
344.74
358.15
umol/l
0.45
85
540
43
219
2.12
4.53
6.1
4.3
0.36
0.78
%
1.59
14
74
19
65
3.05
4.53
2.9
1.3
0.18
0.35
mg/l
—
9
26
45
234
2.08
4.50
2.1
2.1
323.22
134.50
ug/g
1.51
32
183
22
83
2.78
4.43
1.4
1.1
—
—
titre
—
0
0
12
24
5.16
4.36
1.2
1.1
—
—
—
0
0
49
267
1.99
4.32
1.8
1.6
—
—
—
0
0
129
939
1.64
4.27
2.3
2.3
—
—
—
0
0
40
203
2.12
4.26
5.9
4.5
0.42
0.44
%
0.04
12
69
26
110
2.49
4.20
1.7
1.2
—
—
—
0
0
41
213
2.07
4.11
6.2
4.7
0.00
0.33
%
1.34
12
64
135
1016
1.59
3.78
7.4
4.4
0.11
0.05
estimate
0.39
35
244
11
24
4.71
3.78
1.7
1.4
87.32
88.56
%
0.18
11
24
34
171
2.11
3.71
4.9
4.6
—
—
—
0
0
46
259
1.91
3.69
2.9
1.9
0.21
0.20
g/l
0.56
39
240
10
21
4.88
3.58
2.7
2.0
—
—
—
0
0
46
263
1.88
3.52
5.3
3.5
4.07
4.23
e9/l
0.15
37
218
86
590
1.63
3.49
6.9
4.4
1.01
1.02
kg/l
1.53
68
399
11
27
4.19
3.43
1.2
1.3
269.83
278.63
mosm/kgh2o
—
6
19
15
53
2.92
3.41
5.3
1.8
58.93
63.60
%
0.27
15
53
270
2433
1.89
3.39
51.1
21.6
138.56
139.50
mmol/l
4.98
261
2367
270
2433
1.89
3.39
52.5
21.8
3.98
3.99
mmol/l
0.34
261
2364
9
18
5.12
3.39
2.1
1.8
32.76
35.71
%
—
9
18
101
727
1.58
3.35
6.2
3.9
0.03
0.00
estimate
0.38
36
223
9
19
4.85
3.26
1.1
1.8
11.68
10.54
%
—
9
19
9
20
4.60
3.13
2.0
1.4
—
—
—
0
0
36
198
1.93
3.10
1.9
1.5
—
—
—
0
0
17
69
2.55
3.01
1.5
1.2
—
—
—
0
0
101
745
1.53
2.95
16.3
6.2
—
—
—
0
0
268
2434
1.78
2.94
23.8
12.1
22.03
23.73
u/l
1.56
256
2328
271
2474
1.79
2.85
54.1
23.8
80.35
80.08
umol/l
0.04
263
2427
83
591
1.55
2.83
1.5
1.3
—
—
—
0
0
25
125
2.09
2.80
1.2
1.3
—
—
—
0
0
20
92
2.26
2.73
2.6
2.8
532.50
221.48
mg/l
—
8
33
23
113
2.12
2.69
3.8
3.9
—
—
—
0
0
12
43
2.86
2.68
1.4
1.3
—
—
—
0
0
13
49
2.73
2.66
4.1
2.9
—
—
—
0
0
39
232
1.78
2.65
2.6
2.3
0.00
0.07
estimate
—
8
45
259
2349
1.64
2.62
32.3
16.3
—
—
—
0
0
203
1749
1.47
2.61
6.0
4.4
—
0.25
—
0
8
7
15
4.75
2.61
3.3
1.7
0.37
0.39
e9/l
—
7
15
70
490
1.55
2.56
7.2
4.8
—
—
—
0
0
6
11
5.54
2.55
2.8
1.4
54.00
36.00
e6/l
—
6
11
25
130
2.00
2.54
2.6
2.8
—
—
—
0
0
11
37
3.04
2.51
1.3
1.1
—
—
—
0
0
209
1820
1.46
2.47
5.6
4.3
15.64
15.21
pmol/l
1.45
196
1597
271
2496
1.71
2.47
61.8
26.5
92.79
91.51
fl
3.46
263
2451
11
38
2.96
2.44
3.4
2.4
—
—
—
0
0
271
2498
1.71
2.43
61.9
26.6
4.18
4.36
e12/l
6.01
260
2419
271
2498
1.71
2.43
61.8
26.6
7.03
6.82
e9/l
0.86
260
2419
271
2498
1.71
2.43
63.9
26.9
37.45
39.13
%
3.85
263
2451
271
2498
1.71
2.43
61.5
26.6
246.21
243.66
e9/l
0.22
260
2429
271
2498
1.71
2.43
62.5
26.8
125.97
131.23
g/l
6.75
265
2453
271
2498
1.71
2.43
61.7
26.5
30.56
30.28
pg
1.24
263
2452
20
97
2.14
2.43
2.9
2.7
—
—
—
0
0
15
64
2.41
2.43
1.5
1.3
246.22
289.94
ug/g
—
9
41
9
28
3.28
2.32
1.1
1.0
—
—
—
0
0
7
18
3.95
2.26
5.0
2.2
—
—
—
0
0
120
961
1.41
2.19
5.9
3.8
—
0.83
—
0
6
55
378
1.55
2.17
3.3
3.1
0.86
0.84
ug/l
0.06
38
264
244
2216
1.49
2.11
7.8
7.1
41.16
40.39
mmol/mol
0.48
224
2016
7
20
3.56
2.06
4.1
2.5
—
—
—
0
0
12
50
2.46
2.05
1.2
1.2
—
—
—
0
0
250
2293
1.48
1.94
5.9
6.1
2.39
2.55
mmol/l
2.07
223
2053
80
611
1.42
1.87
1.9
1.8
422.44
56965096.19
pmol/l
1.18
62
481
6
17
3.58
1.84
2.2
1.7
13.28
14.32
umol/l
—
6
12
239
2183
1.42
1.81
6.9
5.4
1.91
2.05
mu/l
0.94
224
1928
9
35
2.62
1.81
1.9
1.8
3.31
110.76
u/ml
—
9
35
7
23
3.09
1.81
1.7
1.2
—
—
—
0
0
8
30
2.71
1.73
3.3
2.9
3.72
3.65
e9/l
—
8
30
242
2222
1.42
1.72
5.1
5.1
1.47
1.49
mmol/l
0.35
216
1973
18
97
1.91
1.70
6.6
5.2
—
—
—
0
0
36
238
1.58
1.69
4.1
2.4
0.34
0.76
e6/l
0.53
36
231
8
31
2.62
1.67
1.1
2.0
127.75
215.77
pmol/l
—
8
26
39
264
1.55
1.66
1.3
1.3
—
—
—
0
0
7
25
2.84
1.66
1.3
1.0
—
—
—
0
0
10
41
2.49
1.66
1.3
1.2
—
—
—
0
0
5
14
3.61
1.62
1.4
1.0
—
—
—
0
0
243
2241
1.40
1.62
5.3
5.2
4.32
4.49
mmol/l
1.62
220
2009
10
44
2.31
1.57
3.0
2.8
57.10
58.01
%
—
10
44
7
27
2.63
1.52
1.1
1.0
—
—
—
0
0
30
196
1.59
1.50
6.8
3.2
—
—
—
0
0
232
2134
1.35
1.49
4.4
4.4
1.29
1.25
mmol/l
0.27
199
1874
95
774
1.33
1.47
6.9
4.2
0.00
0.01
estimate
0.50
39
271
9
38
2.41
1.47
1.7
1.4
—
—
—
0
0
9
38
2.41
1.47
1.7
1.4
—
—
—
0
0
9
38
2.41
1.47
1.7
1.4
—
—
—
0
0
9
38
2.41
1.47
1.7
1.4
—
—
—
0
0
6
23
2.64
1.37
1.3
1.8
—
—
—
0
0
6
24
2.53
1.31
1.8
1.4
16.35
15.30
%
—
6
24
8
34
2.39
1.30
2.8
2.1
—
—
—
0
0
81
658
1.31
1.27
6.3
5.4
3.92
2.79
ug/l
0.61
69
585
244
2281
1.34
1.25
5.7
5.5
6.10
6.09
mmol/l
0.04
224
2016
15
85
1.80
1.25
1.3
1.5
—
—
—
0
0
6
25
2.43
1.25
1.0
1.0
—
—
—
0
0
5
19
2.66
1.22
7.4
2.9
0.20
0.89
index
—
5
19
8
38
2.13
1.19
1.4
1.2
—
—
—
0
0
6
26
2.33
1.19
1.3
1.1
—
—
—
0
0
5
20
2.52
1.15
1.2
1.1
—
—
—
0
0
7
30
2.36
1.13
1.1
1.0
—
—
—
0
0
8
40
2.03
1.13
3.5
2.7
—
—
—
0
0
29
203
1.47
1.10
7.2
3.8
—
—
—
0
0
5
22
2.29
1.04
1.2
1.0
—
—
—
0
0
5
23
2.19
0.98
1.2
1.5
7.28
7.68
mmol/l
—
5
23
32
235
1.40
0.96
1.4
1.4
—
—
—
0
0
42
324
1.34
0.95
1.5
1.4
—
—
—
0
0
6
28
2.16
0.92
1.3
1.4
—
—
—
0
0
6
28
2.16
0.92
1.3
1.4
—
—
—
0
0
18
119
1.54
0.90
2.8
2.3
0.00
0.03
estimate
—
6
31
6
30
2.02
0.87
1.3
1.4
—
—
—
0
0
6
30
2.02
0.87
1.3
1.4
—
—
—
0
0
8
46
1.76
0.83
1.5
1.5
—
—
—
0
0
8
48
1.68
0.79
1.5
1.3
—
—
—
0
0
5
24
2.10
0.75
1.0
1.3
—
—
—
0
0
18
125
1.47
0.74
1.2
1.2
—
—
—
0
0
23
170
1.38
0.70
1.3
1.6
—
—
—
0
0
65
755
0.82
0.68
4.0
3.6
—
—
—
0
0
16
112
1.45
0.65
2.2
1.3
180.10
307.41
u/ml
0.53
16
100
5
30
1.68
0.61
1.4
1.3
—
—
—
0
0
15
105
1.45
0.61
1.2
1.5
—
—
—
0
0
6
35
1.73
0.58
1.3
1.3
1.36
0.89
g/l
—
6
35
6
36
1.68
0.57
3.7
1.6
12.00
10.42
mmol/l
—
6
36
6
39
1.55
0.53
1.0
1.3
—
—
—
0
0
32
263
1.24
0.49
9.6
4.4
7.32
7.35
ph
0.10
24
172
17
128
1.35
0.49
2.7
1.8
—
—
—
0
0
80
879
0.88
0.43
3.7
3.3
41.44
49.03
mg/l
0.20
56
561
83
907
0.88
0.41
4.2
4.1
7.28
8.24
mg/mmol
0.13
58
560
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
6
47
1.28
0.32
1.0
1.1
—
—
—
0
0
5
41
1.22
0.22
1.4
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
15.20
—
0
5
0
10
0.00
0.21
0.0
1.0
—
0.56
—
0
5
0
10
0.00
0.21
0.0
2.3
—
0.83
—
0
5
5
43
1.17
0.21
1.6
1.5
—
—
—
0
0
8
69
1.16
0.16
1.0
1.3
—
—
—
0
0
6
76
0.79
0.16
47.0
8.3
—
—
—
0
0
92
938
0.97
0.05
1.9
1.9
1.34
1.32
mmol/l
0.11
82
743
13
137
0.95
0.01
1.3
1.2
32.77
148.35
u/ml
—
6
46
89
894
0.99
0.00
3.5
3.3
6.06
7.01
mmol/l
1.29
74
741
0
5
0.00
0.00
0.0
1.2
—
1.54
—
0
5
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
585.40
—
0
5
0
6
0.00
-0.00
0.0
1.7
—
4.83
—
0
6
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
7
76
0.92
-0.00
1.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
15.89
—
0
7
0
8
0.00
-0.00
0.0
1.0
—
0.00
—
0
8

Mortality – FinRegistry

↥

Association

Association between endpoint M13_VERTEBCOLLAPSE and mortality.

Females

Parameter HR [95% CI] p-value
M13_VERTEBCOLLAPSE 1.885 [1.61, 2.21] < 0.001
Birth year 0.996 [0.99, 1.0] 0.355

During the follow-up period (1.1.1998 — 31.12.2019), 934 out of 1714 females with M13_VERTEBCOLLAPSE died.

Males

Parameter HR [95% CI] p-value
M13_VERTEBCOLLAPSE 2.57 [1.93, 3.42] < 0.001
Birth year 0.987 [0.98, 1.0] 0.008

During the follow-up period (1.1.1998 — 31.12.2019), 507 out of 886 males with M13_VERTEBCOLLAPSE died.

Mortality risk

Mortality risk for people of age

years, who have M13_VERTEBCOLLAPSE.

N-year risk Females Males
1 0.216% 0.475%
5 1.281% 3.061%
10 3.045% 7.447%
15 5.762% 13.539%
20 9.692% 22.336%

Relationships between endpoints

↥

Index endpoint: M13_VERTEBCOLLAPSE – Collapsed vertebra, not elsewhere classified

GWS hits: 2

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data